<SEC-DOCUMENT>0000078003-23-000120.txt : 20231213
<SEC-HEADER>0000078003-23-000120.hdr.sgml : 20231213
<ACCEPTANCE-DATETIME>20231213074452
ACCESSION NUMBER:		0000078003-23-000120
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		15
CONFORMED PERIOD OF REPORT:	20231213
ITEM INFORMATION:		Regulation FD Disclosure
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20231213
DATE AS OF CHANGE:		20231213

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			PFIZER INC
		CENTRAL INDEX KEY:			0000078003
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				135315170
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-03619
		FILM NUMBER:		231482980

	BUSINESS ADDRESS:	
		STREET 1:		66 HUDSON BOULEVARD EAST
		CITY:			NEW YORK
		STATE:			NY
		ZIP:			10001-2192
		BUSINESS PHONE:		2127332323

	MAIL ADDRESS:	
		STREET 1:		66 HUDSON BOULEVARD EAST
		CITY:			NEW YORK
		STATE:			NY
		ZIP:			10001-2192

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	PFIZER CHARLES & CO INC
		DATE OF NAME CHANGE:	19710908
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>pfe-20231213.htm
<DESCRIPTION>8-K DECEMBER 13 2023
<TEXT>
<XBRL>
<?xml version="1.0" ?><!--XBRL Document Created with the Workiva Platform--><!--Copyright 2023 Workiva--><!--r:561d4948-4979-4b6f-ba73-bfebeab2ca2b,g:2bded373-6141-4b85-86a6-c93c11857ae4,d:bdf4ac0691ed41449a44483aec7751e9--><html xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:us-gaap="http://fasb.org/us-gaap/2023" xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns:pfe="http://www.pfizer.com/20231213" xmlns="http://www.w3.org/1999/xhtml" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>pfe-20231213</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="c-1" name="dei:EntityCentralIndexKey" id="f-27">0000078003</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:AmendmentFlag" id="f-28">false</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="pfe-20231213.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="c-1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-12-13</xbrli:startDate><xbrli:endDate>2023-12-13</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-12-13</xbrli:startDate><xbrli:endDate>2023-12-13</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">pfe:NotesDue20271.000Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-12-13</xbrli:startDate><xbrli:endDate>2023-12-13</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="ibdf4ac0691ed41449a44483aec7751e9_1"></div><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">UNITED STATES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Washington, D.C.&#160;&#160;20549</span></div><div><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:700;line-height:120%">FORM <ix:nonNumeric contextRef="c-1" name="dei:DocumentType" id="f-1"><ix:nonNumeric contextRef="c-1" name="dei:DocumentType" id="f-2">8-K</ix:nonNumeric></ix:nonNumeric> </span></div><div><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CURRENT REPORT</span></div><div><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PURSUANT TO SECTION 13 OR 15(d) OF THE</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SECURITIES EXCHANGE ACT OF 1934</span></div><div><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Date of report (Date of earliest event reported): <ix:nonNumeric contextRef="c-1" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="f-3"><ix:nonNumeric contextRef="c-1" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="f-4">December 13, 2023</ix:nonNumeric></ix:nonNumeric></span></div><div><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityRegistrantName" id="f-5"><ix:nonNumeric contextRef="c-1" name="dei:EntityRegistrantName" id="f-6">PFIZER INC</ix:nonNumeric></ix:nonNumeric>.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Exact name of registrant as specified in its charter)</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:31.744%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:33.064%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.892%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen" id="f-7">Delaware</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityFileNumber" id="f-8">1-3619</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityTaxIdentificationNumber" id="f-9">13-5315170</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(State or other</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(Commission File</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(I.R.S. Employer</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">jurisdiction of</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Number)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Identification No.)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">incorporation)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:225.75pt"><tr><td style="width:1.0pt"></td><td style="width:91.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:55.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:72.25pt"></td><td style="width:1.0pt"></td></tr><tr style="height:14pt"><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressAddressLine1" id="f-10">66 Hudson Boulevard East</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressPostalZipCode" id="f-11">10001-2192</ix:nonNumeric></span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressCityOrTown" id="f-12">New York,</ix:nonNumeric> </span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressStateOrProvince" format="ixt-sec:stateprovnameen" id="f-13">New York</ix:nonNumeric> </span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(Zip Code)</span></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Address of principal executive offices)</span></div><div><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Registrant&#8217;s telephone number, including area code:</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(<ix:nonNumeric contextRef="c-1" name="dei:CityAreaCode" id="f-14">212</ix:nonNumeric>) <ix:nonNumeric contextRef="c-1" name="dei:LocalPhoneNumber" id="f-15">733-2323</ix:nonNumeric> </span></div><div><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:44.005%"><tr><td style="width:1.0%"></td><td style="width:40.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:24.481%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.791%"></td><td style="width:0.1%"></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Former name or former address, if changed since last report)</span></div><div style="text-align:center"><span><br/></span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the obligation of the registrant under any of the following provisions (see General Instruction A.2. below):</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:WrittenCommunications" format="ixt-sec:boolballotbox" id="f-16">&#9744;</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:SolicitingMaterial" format="ixt-sec:boolballotbox" id="f-17">&#9744;</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:PreCommencementTenderOffer" format="ixt-sec:boolballotbox" id="f-18">&#9744;</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2 (b))</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:PreCommencementIssuerTenderOffer" format="ixt-sec:boolballotbox" id="f-19">&#9744;</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:31.744%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.744%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.746%"></td><td style="width:0.1%"></td></tr><tr><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%;text-decoration:underline">Securities registered pursuant to Section 12(b) of the Act:</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">Title of each class</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">Trading Symbol(s)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">Name of each exchange on which registered</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-2" name="dei:Security12bTitle" id="f-20">Common Stock, $.05 par value</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-2" name="dei:TradingSymbol" id="f-21">PFE</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-2" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="f-22">New York Stock Exchange</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-3" name="dei:Security12bTitle" id="f-23">1.000% Notes due 2027</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-3" name="dei:TradingSymbol" id="f-24">PFE27</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-3" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="f-25">New York Stock Exchange</ix:nonNumeric></span></td></tr></table></div><div><span><br/></span></div><div style="text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&#167;240.12b-2 of this chapter). </span></div><div><span><br/></span></div><div style="text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Emerging growth company &#160;&#160;&#160;</span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityEmergingGrowthCompany" format="ixt-sec:boolballotbox" id="f-26">&#9744;</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div><span><br/></span></div><div style="margin-top:3pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. &#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9744;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.660%"><tr><td style="width:1.0%"></td><td style="width:11.025%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.666%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.414%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.414%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.414%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.414%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.853%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="21" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Item 7.01. &#160;&#160;&#160;&#160;Regulation FD Disclosure.</span></td></tr><tr><td colspan="21" style="padding:2px 1pt 2px 3.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">On December 13, 2023, Pfizer Inc. issued a press release that provided its full-year 2024 guidance. A copy of the press release is furnished as Exhibit 99.1 hereto and is incorporated herein by reference. <br/></span><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><br/></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The information furnished pursuant to this &#8220;Item 7.01 &#8211; Regulation FD Disclosure&#8221;, including Exhibit 99.1, shall not be deemed to be &#8220;filed&#8221; for the purposes of Section 18 of the Exchange Act or otherwise subject to the liabilities of that section, and shall not be deemed to be incorporated by reference into any filing made by us under the Exchange Act or the Securities Act, regardless of any general incorporation language in any such filing, except as shall be expressly set forth by specific reference in such filing.</span></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.660%"><tr><td style="width:1.0%"></td><td style="width:11.025%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.666%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.414%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.414%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.414%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.414%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.853%"></td><td style="width:0.1%"></td></tr><tr><td colspan="21" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Item 9.01.           Financial Statements and Exhibits. </span></td></tr><tr><td colspan="18" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:2.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(d) Exhibits</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:2.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">Exhibit No.</span></div></td><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">Exhibit Description</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exhibit 99.1</span></td><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:2.25pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exh99pr121323.htm">Press Release of Pfizer Inc. dated December 13, 2023.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104</span></td><td colspan="15" style="padding:2px 1pt 2px 3.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cover Page Interactive Data File--the cover page XBRL tags are embedded within the Inline XBRL document.</span></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="text-align:justify"><span><br/></span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span><br/></span></div><div id="ibdf4ac0691ed41449a44483aec7751e9_7"></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SIGNATURES</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:33.650%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.592%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:59.458%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">PFIZER INC.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">/s/ Margaret M. Madden</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Margaret M. Madden</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior Vice President and Corporate Secretary</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Governance Counsel</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Dated: December 13, 2023</span></div><div><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>exh99pr121323.htm
<DESCRIPTION>EX-99.1 PRESS RELEASE
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="ide13ed212fa24de4b9b558faac084264_1"></div><div style="min-height:72pt;width:100%"><div style="margin-bottom:8pt"><font><br></font></div></div><div style="padding-left:9pt;text-align:right"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:125%">Exhibit 99.1</font></div><div style="margin-bottom:8pt"><font><br></font></div><div style="padding-left:9pt"><img alt="pfizerlogoaa.jpg" src="pfizerlogoaa.jpg" style="height:98px;margin-bottom:5pt;vertical-align:text-bottom;width:228px"></div><div style="padding-left:9pt"><font><br></font></div><div style="padding-left:9pt"><font><br></font></div><div style="margin-bottom:8pt;padding-left:5.6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:45.238%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:52.562%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:16.8pt;padding-right:107pt"><font><br></font></div><div style="padding-left:3.5pt;padding-right:107pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">For Immediate Release </font></div><div style="padding-left:3.5pt;padding-right:107pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">December 13, 2023</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font><br></font></div><div style="padding-left:103.5pt;text-indent:-90pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Media Contact&#58; PfizerMediaRelations&#64;Pfizer.com</font></div><div style="margin-bottom:0.2pt;padding-left:103.5pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#160;+1 (212) 733-1226</font></div><div style="padding-right:6pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#160;&#160;&#160;</font></div><div style="padding-left:13.5pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Investor Contact&#58;   IR&#64;Pfizer.com</font></div><div style="padding-left:108pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">+1 (212) 733-4848</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:125%"> </font></div></td></tr></table></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:133%">Pfizer Provides Full-Year 2024 Guidance</font></div><div><font><br></font></div><div style="padding-left:18pt;text-indent:-18pt"><font style="font-family:'Wingdings',sans-serif;font-size:11pt;font-weight:400;line-height:174%"></font><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:174%;padding-left:12.97pt">Full-Year 2024 Revenue Guidance</font><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:7.15pt;font-weight:400;line-height:174%;position:relative;top:-3.85pt;vertical-align:baseline">(1)</font><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:174%"> Range of $58.5 to $61.5 Billion Includes Expected Contribution from Seagen Acquisition</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:174%">-</font><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:174%;padding-left:14.64pt">Anticipates Approximately $8 Billion in Revenues for Comirnaty</font><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:7.15pt;font-weight:400;line-height:174%;position:relative;top:-3.85pt;vertical-align:baseline">(2)</font><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:174%"> and Paxlovid </font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:174%">-</font><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:174%;padding-left:14.64pt">Seagen Expected to Contribute Approximately $3.1 Billion of Revenues</font></div><div style="padding-left:18pt;text-indent:-18pt"><font style="font-family:'Wingdings',sans-serif;font-size:11pt;font-weight:400;line-height:174%"></font><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:174%;padding-left:12.97pt">Expects Full-Year 2024 Operational</font><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:7.15pt;font-weight:400;line-height:174%;position:relative;top:-3.85pt;vertical-align:baseline">(3)</font><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:174%"> Revenue Growth of 8%-10% Including Seagen Contribution and Excluding Comirnaty</font><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:7.15pt;font-weight:400;line-height:174%;position:relative;top:-3.85pt;vertical-align:baseline">(2)</font><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:174%"> and Paxlovid Revenues, and 3%-5% Excluding Both Seagen Contribution and Comirnaty</font><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:7.15pt;font-weight:400;line-height:174%;position:relative;top:-3.85pt;vertical-align:baseline">(2)</font><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:174%"> and Paxlovid Revenues </font></div><div style="margin-bottom:3pt;padding-left:18pt;text-indent:-18pt"><font style="font-family:'Wingdings',sans-serif;font-size:11pt;font-weight:400;line-height:174%"></font><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:174%;padding-left:12.97pt">2024 Adjusted</font><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:7.15pt;font-weight:400;line-height:174%;position:relative;top:-3.85pt;vertical-align:baseline">(5)</font><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:174%"> Diluted EPS Guidance Range of $2.05 to $2.25 Includes Expected Impact of Seagen Acquisition</font></div><div style="margin-bottom:3pt;padding-left:18pt;text-indent:-18pt"><font style="font-family:'Wingdings',sans-serif;font-size:11pt;font-weight:400;line-height:174%"></font><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:174%;padding-left:12.97pt">Enterprise-Wide Cost Realignment Program Now Expected to Deliver Annual Net Cost Savings of at Least $4.0 Billion, an Incremental $500 Million Versus Mid-Point of Guidance Range Provided on August 1, 2023</font></div><div style="padding-left:18pt;text-indent:-18pt"><font style="font-family:'Wingdings',sans-serif;font-size:11pt;font-weight:400;line-height:100%"></font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:12.97pt">Pfizer to Hold Analyst and Investor Call at 8&#58;30 a.m. EST on Wednesday, December 13, 2023</font></div><div style="padding-left:18pt"><font><br></font></div><div style="margin-bottom:6pt;padding-left:2.15pt"><font><br></font></div><div><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:174%">NEW YORK, December 13, 2023</font><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:174%"> &#8212; Pfizer Inc. (NYSE&#58;PFE) today provided its full-year 2024 guidance</font><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:7.15pt;font-weight:400;line-height:174%;position:relative;top:-3.85pt;vertical-align:baseline">(1)(6)</font><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:174%">, which includes the expected financial impact from the Seagen transaction.</font></div><div style="margin-top:6pt"><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:174%">Accompanying presentation can be found at www.pfizer.com&#47;investors. </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:8pt"><font><br></font></div></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:174%">Full-Year 2024 Revenue, Adjusted</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.15pt;font-weight:700;line-height:174%;position:relative;top:-3.85pt;vertical-align:baseline">(5)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:174%"> SI&#38;A, Adjusted</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.15pt;font-weight:700;line-height:174%;position:relative;top:-3.85pt;vertical-align:baseline">(5)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:174%"> R&#38;D and Adjusted</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.15pt;font-weight:700;line-height:174%;position:relative;top:-3.85pt;vertical-align:baseline">(5)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:174%"> Diluted EPS Guidance Ranges</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.15pt;font-weight:700;line-height:174%;position:relative;top:-3.85pt;vertical-align:baseline">(1)(6)</font></div><div><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:174%">Pfizer expects full-year 2024 revenues to be in the range of $58.5 to $61.5 billion, which includes approximately $8 billion in anticipated revenues for Comirnaty</font><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:7.15pt;font-weight:400;line-height:174%;position:relative;top:-3.85pt;vertical-align:baseline">(2)</font><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:174%"> and Paxlovid, approximately $3.1 billion in anticipated revenues from Seagen and approximately $1 billion related to the reclassification of Pfizer&#8217;s royalty income from Other (Income)&#47;Deductions into the Revenue line. Including the contribution from Seagen and excluding revenues from Comirnaty</font><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:7.15pt;font-weight:400;line-height:174%;position:relative;top:-3.85pt;vertical-align:baseline">(2)</font><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:174%"> and Paxlovid, Pfizer expects to achieve full-year 2024 operational</font><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:7.15pt;font-weight:400;line-height:174%;position:relative;top:-3.85pt;vertical-align:baseline">(3)</font><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:174%"> revenue growth of 8% to 10%. Excluding revenues from Comirnaty</font><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:7.15pt;font-weight:400;line-height:174%;position:relative;top:-3.85pt;vertical-align:baseline">(2)</font><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:174%"> and Paxlovid and the expected contribution from Seagen, Pfizer expects to achieve full-year 2024 operational</font><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:7.15pt;font-weight:400;line-height:174%;position:relative;top:-3.85pt;vertical-align:baseline">(3)</font><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:174%"> revenue growth of 3% to 5%. Both expected operational</font><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:7.15pt;font-weight:400;line-height:174%;position:relative;top:-3.85pt;vertical-align:baseline">(3)</font><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:174%"> growth rate ranges are compared with the mid-point of Pfizer&#8217;s full-year 2023 revenue guidance range provided on October 31, 2023, and account for the reclassification of royalty income. While the company will begin reporting royalty income in the revenue line in 2024, for growth rate purposes, the company has included royalty income in both 2023 and 2024. Consequently, there is no operational revenue growth attributable to the reclassification of royalty income.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:174%">Including the impact of Seagen, Pfizer anticipates full-year 2024 Adjusted</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.15pt;font-weight:400;line-height:174%;position:relative;top:-3.85pt;vertical-align:baseline">(5)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:174%"> SI&#38;A expenses to be in the range of $13.8 billion to $14.8 billion and full-year 2024 Adjusted</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.15pt;font-weight:400;line-height:174%;position:relative;top:-3.85pt;vertical-align:baseline">(5)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:174%"> R&#38;D expenses to be in the range of $11.0 to $12.0 billion. Consequently, total 2024 Adjusted</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.15pt;font-weight:400;line-height:174%;position:relative;top:-3.85pt;vertical-align:baseline">(5)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:174%"> SI&#38;A and R&#38;D expenses are expected to be in the range of $24.8 to $26.8 billion. This range reflects an anticipated decline of approximately $4 billion by the end of 2024 and represents an incremental $500 million expense reduction versus the midpoint of Pfizer&#8217;s SI&#38;A and R&#38;D expense guidance provided on August 1, 2023, solely driven by Pfizer&#8217;s cost realignment program.</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:174%">2024 Adjusted</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.15pt;font-weight:400;line-height:174%;position:relative;top:-3.85pt;vertical-align:baseline">(5)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:174%"> diluted EPS is anticipated to be in a range of $2.05 to $2.25, which primarily reflects expected operational</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.15pt;font-weight:400;line-height:174%;position:relative;top:-3.85pt;vertical-align:baseline">(3)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:174%"> growth of 8%-10% in revenues, excluding Comirnaty</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.15pt;font-weight:400;line-height:174%;position:relative;top:-3.85pt;vertical-align:baseline">(2)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:174%"> and Paxlovid, and including the impact of Seagen, as well as anticipated operating margin improvement from the company&#8217;s cost realignment activities, partially offset by an expected $0.40 dilutive impact related to the Seagen acquisition, which is predominantly driven by costs to finance the transaction.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:174%">A reconciliation of Pfizer&#8217;s 2023 Financial Guidance to its 2024 Financial Guidance</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.15pt;font-weight:400;line-height:174%;position:relative;top:-3.85pt;vertical-align:baseline">(1)(6)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:174%">, including certain significant factors impacting 2024 Financial Guidance, is presented below. </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:8pt"><font><br></font></div></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:174%"><br></font><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.358%"><tr><td style="width:1.0%"></td><td style="width:20.674%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.738%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.480%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.708%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023 Pfizer Guidance (as of October 31, 2023)</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024 Legacy Pfizer</font></div><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Guidance</font></div></td><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Anticipated Impact of Royalty Reclass included in 2024 Guidance</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Anticipated 2024</font></div><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Seagen Impact included in 2024 Guidance</font></div></td><td colspan="3" style="border-left:1.5pt solid #000000;border-right:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024 Financial Guidance</font></td></tr><tr><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Revenues ($ in billions)</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$58.0 &#8211; $61.0</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$54.5 &#8211; $57.5</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$1.0</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$3.1</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$58.5 &#8211; $61.5</font></td></tr><tr><td colspan="3" style="border-left:1.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:3pt;margin-top:6pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:133%">Adjusted</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:133%;position:relative;top:-3.5pt;vertical-align:baseline">(5)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:133%"> SI&#38;A</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:133%"> </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:133%">Expenses</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:133%;position:relative;top:-3.5pt;vertical-align:baseline"> </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:133%">($ in billions)</font></div></td><td colspan="3" style="border-left:1.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$13.3 &#8211; $14.3</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:1.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$13.8 &#8211; $14.8</font></td></tr><tr><td colspan="3" style="border-left:1.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:3pt;margin-top:6pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:133%">Adjusted</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:133%;position:relative;top:-3.5pt;vertical-align:baseline">(5)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:133%"> R&#38;D Expenses</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:133%;position:relative;top:-3.5pt;vertical-align:baseline"> </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:133%">($ in billions)</font></div></td><td colspan="3" style="border-left:1.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$11.9 &#8211; $12.9</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:1.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$11.0 &#8211; $12.0</font></td></tr><tr><td colspan="3" style="border-left:1.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:3pt;margin-top:6pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:133%">Effective Tax Rate on Adjusted</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:133%;position:relative;top:-3.5pt;vertical-align:baseline">(5)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:133%"> Income</font></div></td><td colspan="3" style="border-left:1.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#126;12%</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:1.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#126;15%</font></td></tr><tr><td colspan="3" style="border-bottom:1.5pt solid #000000;border-left:1.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:3pt;margin-top:6pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:133%">Adjusted</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:133%;position:relative;top:-3.5pt;vertical-align:baseline">(5)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:133%"> Diluted EPS</font></div></td><td colspan="3" style="border-bottom:1.5pt solid #000000;border-left:1.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$1.45 &#8211; $1.65</font></td><td colspan="3" style="border-bottom:1.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$2.45 &#8211; $2.65</font></td><td colspan="3" style="border-bottom:1.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">-</font></td><td colspan="3" style="border-bottom:1.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">($0.40)</font></td><td colspan="3" style="border-bottom:1.5pt solid #000000;border-left:0.5pt solid #000000;border-right:1.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$2.05 &#8211; $2.25</font></td></tr></table></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:174%">Financial guidance for Adjusted</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.15pt;font-weight:400;line-height:174%;position:relative;top:-3.85pt;vertical-align:baseline">(5)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:174%"> diluted EPS is calculated using approximately 5.75 billion weighted average shares outstanding, and assumes no share repurchases in 2023 or 2024.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:174%">Seagen Acquisition</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:174%">As announced on December 12, 2023,</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:174%"> </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:174%">Pfizer and Seagen have received all required regulatory approvals for the closing of the acquisition.  Pfizer expects to complete the acquisition of Seagen on December 14, 2023, subject to the satisfaction of other customary closing conditions.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:174%">Executive Commentary</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:174%">Dr. Albert Bourla, Pfizer Chairman and Chief Executive Officer, stated&#58; &#8220;Pfizer&#8217;s product portfolio remains strong. In 2024, Comirnaty and Paxlovid are expected to deliver combined revenues of approximately $8 billion and our remaining portfolio of combined Pfizer and Seagen products is expected to achieve year-over-year operational revenue growth in the range of 8% to 10%.</font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">3</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:8pt"><font><br></font></div></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:174%">&#8220;In addition, we expect our cost realignment program to deliver savings of at least $4.0 billion by the end of 2024, which puts us on a path to potentially regain our pre-pandemic operating margins. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:174%">&#8220;We look forward to joining forces with Seagen and using our combined strengths to bring us ever closer to delivering long promised cures for certain cancers.&#8221; </font></div><div><font><br></font></div><div><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:174%">Pfizer intends to provide additional commentary in an analyst webcast scheduled for 8&#58;30 a.m. EST, Wednesday, December 13, 2023, details can be found at www.pfizer.com&#47;investors.</font></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:174%"># # #</font></div><div style="margin-bottom:6pt;margin-top:5pt;padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:174%">(1)</font><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:174%;padding-left:5.78pt">Pfizer does not provide guidance for GAAP Reported financial measures (other than revenues and in 2023 acquired in-process R&#38;D &#91;IPR&#38;D&#93; expenses) or a reconciliation of forward-looking non-GAAP financial measures to the most directly comparable GAAP Reported financial measures on a forward-looking basis because it is unable to predict with reasonable certainty the ultimate outcome of unusual gains and losses, certain acquisition-related expenses, gains and losses from equity securities, actuarial gains and losses from pension and postretirement plan remeasurements, potential future asset impairments and pending litigation without unreasonable effort. These items are uncertain, depend on various factors, and could have a material impact on GAAP Reported results for the guidance period.</font></div><div style="margin-bottom:6pt;margin-top:5pt;padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:174%">(2)</font><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:174%;padding-left:5.78pt">As used in this document, &#8220;Comirnaty&#8221; refers to, as applicable, and as authorized or approved, the Pfizer-BioNTech COVID-19 Vaccine, the Pfizer-BioNTech COVID-19 Vaccine, Bivalent (Original and Omicron BA.4&#47;BA.5), Comirnaty (COVID-19 Vaccine, mRNA, 2023-2024 Formula), the Pfizer-BioNTech COVID-19 Vaccine (2023-2024 Formula), Comirnaty Original&#47;Omicron BA.1, Comirnaty Original&#47;Omicron BA.4&#47;BA.5 and Comirnaty XBB.1.5. &#8220;Comirnaty&#8221; includes direct sales and alliance revenues related to sales of the above-mentioned vaccines, which are recorded within Pfizer&#8217;s Primary Care customer group. It does not include revenues for certain Comirnaty-related manufacturing activities performed on behalf of BioNTech, which are included in the Pfizer CentreOne contract development and manufacturing organization. </font></div><div style="margin-bottom:6pt;margin-top:5pt;padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:174%">(3)</font><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:174%;padding-left:5.78pt">References to operational variances in this press release pertain to period-over-period changes that exclude the impact of foreign exchange rates. Although exchange rate changes are part of Pfizer&#8217;s business, they are not within Pfizer&#8217;s control, and because they can mask positive or negative trends in the business, Pfizer believes presenting operational variances excluding these foreign exchange changes provides useful information to evaluate Pfizer&#8217;s results.</font></div><div style="margin-bottom:6pt;margin-top:5pt;padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:174%">(4)</font><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:174%;padding-left:5.78pt">Revenues is defined as revenues in accordance with U.S. generally accepted accounting principles (GAAP).&#160; Reported net income and its components are defined as net income attributable to Pfizer </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">4</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:8pt"><font><br></font></div></div><div style="margin-bottom:6pt;margin-top:5pt;padding-left:18pt"><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:174%">Inc. common shareholders and its components in accordance with U.S. GAAP. Reported diluted earnings per share (EPS) is defined as diluted EPS attributable to Pfizer Inc. common shareholders in accordance with U.S. GAAP.</font></div><div style="margin-bottom:6pt;margin-top:5pt;padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:174%">(5)</font><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:174%;padding-left:5.78pt">Adjusted income and Adjusted diluted EPS are defined as U.S. GAAP net income attributable to Pfizer Inc. common shareholders and Reported diluted EPS attributable to Pfizer Inc. common shareholders before the impact of amortization of intangible assets, certain acquisition-related items, discontinued operations, and certain significant items. Adjusted income and its components and Adjusted diluted EPS measures are not, and should not be viewed as, substitutes for U.S. GAAP net income and its components and diluted EPS</font><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:174%;position:relative;top:-3.5pt;vertical-align:baseline">(4)</font><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:174%">, have no standardized meaning prescribed by U.S. GAAP and may not be comparable to the calculation of similar measures of other companies. See the </font><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:174%">Non-GAAP Financial Measure&#58; Adjusted Income </font><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:174%">section of Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations in Pfizer&#8217;s 2022 Annual Report on Form 10-K for a definition of each component of Adjusted income as well as other relevant information. </font></div><div style="padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:174%">(6)</font><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:174%;padding-left:5.78pt">Financial guidance for full-year 2024 reflects the following&#58;</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:174%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:174%;padding-left:14.5pt">Exchange rates assumed are actual rates at mid-November 2023</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:174%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:174%;padding-left:14.5pt">Guidance for Adjusted</font><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:174%;position:relative;top:-3.5pt;vertical-align:baseline">(5)</font><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:174%"> diluted EPS assumes diluted weighted-average shares outstanding of approximately 5.75 billion shares, and assumes no share repurchases in 2024.</font></div><div><font><br></font></div><div style="margin-bottom:5pt;margin-top:5pt"><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:174%">DISCLOSURE NOTICE&#58; </font><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:174%">The information contained in this press release is as of December 13, 2023. Pfizer assumes no obligation to update forward-looking statements contained in this release or the webcast as the result of new information or future events or developments. Pfizer&#8217;s financial guidance is based on estimates and assumptions that are subject to significant uncertainties. </font></div><div style="margin-bottom:5pt;margin-top:5pt"><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:174%">This press release and the webcast contain or may contain forward-looking information about, among other topics, Pfizer&#8217;s and Seagen&#8217;s anticipated operating and financial performance and expectations for Pfizer&#8217;s and Seagen&#8217;s product pipeline, in-line products and product candidates (including revenue contribution and related projections and guidance), financial and other impact of Pfizer&#8217;s proposed acquisition of Seagen, Pfizer&#8217;s efforts to combat COVID-19, Paxlovid, Pfizer&#8217;s and BioNTech&#8217;s COVID-19 vaccines, defined collectively herein as Comirnaty (including their potential benefits), changes to Pfizer&#8217;s commercial organization, reorganizations, business plans, strategy and prospects, and an enterprise-wide cost realignment program (including anticipated costs, savings and potential benefits) that involves substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. Risks and uncertainties include, among other things, uncertainties regarding the commercial success of Pfizer&#8217;s and Seagen&#8217;s products or product candidates, including Paxlovid and Comirnaty&#59; the uncertainties inherent in research and development, including the ability to meet anticipated clinical endpoints, commencement and&#47;or completion dates for our clinical trials, regulatory submission dates, regulatory approval dates and&#47;or launch dates, as well as risks associated </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">5</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:8pt"><font><br></font></div></div><div style="margin-bottom:5pt;margin-top:5pt"><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:174%">with pre-clinical and clinical data (including Phase 1&#47;2&#47;3 or Phase 4 data for any of Pfizer&#8217;s and Seagen&#8217;s products or product candidates) in any of our studies in pediatrics, adolescents, or adults or real world evidence, including the possibility of unfavorable new pre-clinical, clinical or safety data and further analyses of existing pre-clinical, clinical or safety data or further information regarding the quality of pre-clinical, clinical or safety data&#59; risks associated with interim data&#59; the risk that clinical trial data are subject to differing interpretations and assessments by regulatory authorities&#59; the ability to produce comparable clinical or other results for any of Pfizer&#8217;s and Seagen&#8217;s products or product candidates, including the rate of effectiveness and&#47;or efficacy, safety and tolerability profile observed to date, in additional analyses of the Phase 3 trial for any such products and additional studies, in real world data studies or in larger, more diverse populations following commercialization&#59; the ability of Comirnaty, any vaccine candidate or any future vaccine to prevent, or Paxlovid or any future COVID-19 treatment to be effective against, COVID-19 caused by emerging virus variants&#59; the risk that use of Comirnaty or Paxlovid will lead to new information about efficacy, safety or other developments, including the risk of additional adverse reactions, some of which may be serious&#59; the risk that pre-clinical and clinical trial data are subject to differing interpretations and assessments, including during the peer review&#47;publication process, in the scientific community generally, and by regulatory authorities&#59; whether and when additional data from the BNT162 mRNA vaccine program, Paxlovid or other COVID-19 programs will be published in scientific journal publications and, if so, when and with what modifications and interpretations&#59; whether regulatory authorities will be satisfied with the design of and results from existing or future pre-clinical and clinical studies&#59; whether and when any drug applications or submissions to request emergency use or conditional marketing authorization for any potential indications for any of Pfizer&#8217;s or Seagen&#8217;s products or product candidates may be filed in particular jurisdictions and if obtained, whether or when such emergency use authorization or licenses will expire or terminate&#59; whether and when submissions to request emergency use or conditional marketing authorizations for any vaccine or any vaccine candidate or any potential future vaccines (including potential future annual boosters or re-vaccinations), and&#47;or biologics license and&#47;or emergency use authorization applications or amendments to any such applications may be filed in particular jurisdictions for any vaccine, any vaccine candidate or any potential future vaccines, and if obtained, whether or when such emergency use authorizations or licenses, or existing emergency use authorizations, will expire or terminate&#59; whether and when any applications that may be pending or filed for any of Pfizer&#8217;s or Seagen&#8217;s products or product candidates (including any requested amendments to the emergency use or conditional marketing authorizations) may be approved by particular regulatory authorities, which will depend on myriad factors, including making a determination as to whether the product's benefits outweigh its known risks and determination of the product's efficacy and, if approved, whether any of Pfizer&#8217;s or Seagen&#8217;s products or product candidates for any such indications will be commercially successful&#59; intellectual property and other litigation&#59; decisions by regulatory authorities impacting labeling, manufacturing processes, safety and&#47;or other matters that could affect the availability or commercial potential of any of Pfizer&#8217;s or Seagen&#8217;s products or product candidates, including the </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">6</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:8pt"><font><br></font></div></div><div style="margin-bottom:5pt;margin-top:5pt"><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:174%">authorization or approval of products or therapies developed by other companies&#59; disruptions in the relationships between us and our collaboration partners, clinical trial sites or third-party suppliers, including Pfizer&#8217;s relationship with BioNTech&#59; the risk that demand for any of Pfizer&#8217;s or Seagen&#8217;s products may be reduced, no longer exist or not meet expectations, which may lead to reduced revenues, excess inventory on-hand and&#47;or in the channel which, for Paxlovid and Comirnaty, has resulted in a significant inventory write-off in the third quarter of 2023 and could continue to result in inventory write-offs or other unanticipated charges&#59; challenges related to and uncertainties regarding the transition to the commercial market for any of our products, and in particular, Paxlovid&#59; uncertainties related to the public&#8217;s adherence to vaccines and boosters&#59; risks related to our ability to achieve our revenue forecasts for any of Pfizer&#8217;s or Seagen&#8217;s products or product candidates&#59; the risk that other companies may produce superior or competitive products&#59; risks related to the availability of raw materials to manufacture or test any of Pfizer&#8217;s or Seagen&#8217;s products or product candidates&#59; challenges related to Pfizer&#8217;s vaccine&#8217;s formulation, dosing schedule and attendant storage, distribution and administration requirements, including risks related to storage and handling after delivery by Pfizer&#59; the risk that we may not be able to successfully develop other vaccine formulations, booster treatment courses or potential future annual boosters or re-vaccinations or new variant-based or next generation vaccines or potential combination respiratory vaccines or next generation COVID-19 treatments&#59;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:174%"> </font><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:174%">the risk that we may not be able to recoup costs associated with our R&#38;D and manufacturing efforts&#59; risks associated with any changes in the way we approach or provide research funding for any of our programs&#59; challenges and risks associated with the pace of our development programs&#59; the risk that we may not be able to maintain manufacturing capacity or access to logistics or supply channels commensurate with global demand, which would negatively impact our ability to supply our COVID-19 or other products&#59; whether and when additional supply or purchase agreements will be reached or existing agreements will be completed or renegotiated&#59; uncertainties regarding the ability to obtain recommendations from vaccine or treatment advisory or technical committees and other public health authorities and uncertainties regarding the commercial impact of any such recommendations&#59; pricing and access challenges&#59; challenges related to public confidence in, or awareness of any of Pfizer&#8217;s or Seagen&#8217;s products or product candidates&#59; uncertainties around future changes to applicable healthcare policies and guidelines issued by the U.S. federal government in connection with the declared termination of the federal government&#8217;s COVID-19 public health emergency as of May 11, 2023&#59; trade restrictions&#59; potential third party royalties or other claims&#59; other business effects and uncertainties and the uncertainties inherent in business and financial planning, including the effects of industry, market, business, economic, political or regulatory conditions, risks related to Pfizer&#8217;s business and prospects, adverse developments in Pfizer&#8217;s markets, or adverse developments in the U.S. or global capital markets, credit markets, regulatory environment or economies generally&#59; changes in tax and other laws, regulations, rates and policies&#59; future business combinations or disposals&#59; uncertainties regarding the impact of COVID-19 on our business, operations and financial results&#59; competitive developments&#59; risks related to the satisfaction or waiver of the conditions to closing </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">7</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:8pt"><font><br></font></div></div><div style="margin-bottom:5pt;margin-top:5pt"><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:174%">the proposed acquisition of Seagen in the anticipated timeframe or at all, including the possibility that the proposed acquisition does not close&#59; risks related to the ability to realize the anticipated benefits of the proposed acquisition, including the possibility that the expected benefits from the acquisition will not be realized or will not be realized within the expected time period&#59; the risk that the businesses will not be integrated successfully&#59; disruption from the transaction making it more difficult to maintain business and operational relationships&#59; negative effects of the consummation of the proposed acquisition on the market price of Pfizer&#8217;s common stock and&#47;or operating results&#59; significant transaction costs&#59; unknown liabilities&#59; the risk of litigation and&#47;or regulatory actions related to the proposed acquisition or Seagen&#8217;s business&#59; risks related to the financing of the transaction&#59; uncertainties regarding the impact, success and associated costs of our enterprise-wide cost realignment  program&#59; and the impact of and risks and uncertainties related to restructurings and internal reorganizations, as well as any other corporate strategic initiatives and growth strategies, and cost-reduction and productivity initiatives, each of which requires upfront costs but may fail to yield anticipated benefits and may result in unexpected costs, organizational disruption or other unintended consequences.</font></div><div style="margin-bottom:8pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:174%">A further description of these and other risks and uncertainties can be found in Pfizer&#8217;s Annual Report on Form 10-K for the fiscal year ended December 31, 2022, and in its subsequent reports on Form 10-Q, including in the sections thereof captioned &#8220;Risk Factors&#8221; and &#8220;Forward-Looking Information and Factors That May Affect Future Results&#8221;, as well as in its subsequent reports on Form 8-K, all of which are filed with the U.S. Securities and Exchange Commission and available at www.sec.gov and www.pfizer.com. See also the Overview of Our Performance, Operating Environment, Strategy and Outlook &#8212; Our 2022 Performance and &#8212; The Global Economic Environment sections of Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations (MD&#38;A) in Pfizer&#8217;s 2022 Annual Report on Form 10-K&#59; and the Overview of Our Performance, Operating Environment, Strategy and Outlook &#8212; Our Third Quarter 2023 and First Nine Months of 2023 Performance and &#8212; The Global Economic Environment sections of MD&#38;A in Pfizer&#8217;s Quarterly Report on Form 10-Q for the quarterly period ended October 1, 2023 (available at www.pfizer.com). </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">8</font></div><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>3
<FILENAME>pfe-20231213.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2023 Workiva-->
<!--r:561d4948-4979-4b6f-ba73-bfebeab2ca2b,g:2bded373-6141-4b85-86a6-c93c11857ae4-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:pfe="http://www.pfizer.com/20231213" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dtr-types1="http://www.xbrl.org/dtr/type/2020-01-21" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.pfizer.com/20231213">
  <xs:import namespace="http://fasb.org/us-gaap/2023" schemaLocation="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd"/>
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2023" schemaLocation="https://xbrl.sec.gov/dei/2023/dei-2023.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="pfe-20231213_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="pfe-20231213_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="pfe-20231213_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="CoverPage" roleURI="http://www.pfizer.com/role/CoverPage">
        <link:definition>0000001 - Document - Cover Page</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:element id="pfe_NotesDue20271.000Member" abstract="true" name="NotesDue20271.000Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>4
<FILENAME>pfe-20231213_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2023 Workiva-->
<!--r:561d4948-4979-4b6f-ba73-bfebeab2ca2b,g:2bded373-6141-4b85-86a6-c93c11857ae4-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <link:roleRef roleURI="http://www.pfizer.com/role/CoverPage" xlink:type="simple" xlink:href="pfe-20231213.xsd#CoverPage"/>
  <link:definitionLink xlink:role="http://www.pfizer.com/role/CoverPage" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInformationLineItems_b2d98124-317f-497a-806d-41db84de2a71" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityInformationLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_6ca4c5e8-d4ae-42e6-bb38-cd58a5df464b" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_b2d98124-317f-497a-806d-41db84de2a71" xlink:to="loc_dei_Security12bTitle_6ca4c5e8-d4ae-42e6-bb38-cd58a5df464b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_2b02f45d-f9fc-4036-b185-3c0b6b07f9c5" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_b2d98124-317f-497a-806d-41db84de2a71" xlink:to="loc_dei_DocumentType_2b02f45d-f9fc-4036-b185-3c0b6b07f9c5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_a43b0c24-576b-4c6e-89eb-ca651f115e71" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_b2d98124-317f-497a-806d-41db84de2a71" xlink:to="loc_dei_DocumentPeriodEndDate_a43b0c24-576b-4c6e-89eb-ca651f115e71" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_28d1a50c-544f-4ac8-bb10-6aa2ed247976" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_b2d98124-317f-497a-806d-41db84de2a71" xlink:to="loc_dei_EntityRegistrantName_28d1a50c-544f-4ac8-bb10-6aa2ed247976" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_004d5800-7160-40f7-9b5e-9f4018a2ac00" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_b2d98124-317f-497a-806d-41db84de2a71" xlink:to="loc_dei_EntityIncorporationStateCountryCode_004d5800-7160-40f7-9b5e-9f4018a2ac00" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_97d61ff7-39bb-48e0-87f2-134f361ba640" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_b2d98124-317f-497a-806d-41db84de2a71" xlink:to="loc_dei_EntityFileNumber_97d61ff7-39bb-48e0-87f2-134f361ba640" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_51cb6063-fa5c-44dc-9659-5950ea3cb85e" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_b2d98124-317f-497a-806d-41db84de2a71" xlink:to="loc_dei_EntityTaxIdentificationNumber_51cb6063-fa5c-44dc-9659-5950ea3cb85e" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_ab51c8f6-3faa-4944-97a6-6e129f2b9fd7" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_b2d98124-317f-497a-806d-41db84de2a71" xlink:to="loc_dei_EntityAddressAddressLine1_ab51c8f6-3faa-4944-97a6-6e129f2b9fd7" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_4237bb69-39f6-4746-a4ac-4e885a8dd4e8" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_b2d98124-317f-497a-806d-41db84de2a71" xlink:to="loc_dei_EntityAddressCityOrTown_4237bb69-39f6-4746-a4ac-4e885a8dd4e8" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_78c83c61-2a2b-4c07-bb54-7e784b370519" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_b2d98124-317f-497a-806d-41db84de2a71" xlink:to="loc_dei_EntityAddressStateOrProvince_78c83c61-2a2b-4c07-bb54-7e784b370519" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_fb183b6d-1ba3-40e2-8743-5cce02dabe8a" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_b2d98124-317f-497a-806d-41db84de2a71" xlink:to="loc_dei_EntityAddressPostalZipCode_fb183b6d-1ba3-40e2-8743-5cce02dabe8a" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_dea86abb-8735-42e7-b779-ade7452a0590" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_b2d98124-317f-497a-806d-41db84de2a71" xlink:to="loc_dei_CityAreaCode_dea86abb-8735-42e7-b779-ade7452a0590" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_a542bd1f-7237-449a-97c5-56ec0c1de846" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_b2d98124-317f-497a-806d-41db84de2a71" xlink:to="loc_dei_LocalPhoneNumber_a542bd1f-7237-449a-97c5-56ec0c1de846" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_WrittenCommunications_a9a67409-f0a7-474b-a5fd-2d0a67fb2429" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_WrittenCommunications"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_b2d98124-317f-497a-806d-41db84de2a71" xlink:to="loc_dei_WrittenCommunications_a9a67409-f0a7-474b-a5fd-2d0a67fb2429" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SolicitingMaterial_6beb3048-b09c-4791-87f9-a14164c893a4" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SolicitingMaterial"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_b2d98124-317f-497a-806d-41db84de2a71" xlink:to="loc_dei_SolicitingMaterial_6beb3048-b09c-4791-87f9-a14164c893a4" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementTenderOffer_406e3778-0db3-4e21-9d0c-4b2d1ed26d23" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementTenderOffer"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_b2d98124-317f-497a-806d-41db84de2a71" xlink:to="loc_dei_PreCommencementTenderOffer_406e3778-0db3-4e21-9d0c-4b2d1ed26d23" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementIssuerTenderOffer_b6417c19-3ca8-4f85-bcff-4abd4dc1cd40" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementIssuerTenderOffer"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_b2d98124-317f-497a-806d-41db84de2a71" xlink:to="loc_dei_PreCommencementIssuerTenderOffer_b6417c19-3ca8-4f85-bcff-4abd4dc1cd40" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_b8c81146-773b-49c4-9fd3-f040607314f1" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_b2d98124-317f-497a-806d-41db84de2a71" xlink:to="loc_dei_EntityEmergingGrowthCompany_b8c81146-773b-49c4-9fd3-f040607314f1" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_ffa42d0a-d4ec-460f-aee9-af22d51d361a" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_b2d98124-317f-497a-806d-41db84de2a71" xlink:to="loc_dei_AmendmentFlag_ffa42d0a-d4ec-460f-aee9-af22d51d361a" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_dd2b3128-008a-4ce3-a1c5-c8884a1728ec" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_b2d98124-317f-497a-806d-41db84de2a71" xlink:to="loc_dei_EntityCentralIndexKey_dd2b3128-008a-4ce3-a1c5-c8884a1728ec" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_31a8b980-62f9-473c-a079-d7a6cf815433" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_b2d98124-317f-497a-806d-41db84de2a71" xlink:to="loc_dei_TradingSymbol_31a8b980-62f9-473c-a079-d7a6cf815433" xlink:type="arc" order="20"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_7b8a6f00-8012-42d5-a343-7dbcdfacb735" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_b2d98124-317f-497a-806d-41db84de2a71" xlink:to="loc_dei_SecurityExchangeName_7b8a6f00-8012-42d5-a343-7dbcdfacb735" xlink:type="arc" order="21"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitiesTable_dc0a7a6d-1bce-4b56-9c47-1c17c42ec860" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntitiesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_dei_EntityInformationLineItems_b2d98124-317f-497a-806d-41db84de2a71" xlink:to="loc_dei_EntitiesTable_dc0a7a6d-1bce-4b56-9c47-1c17c42ec860" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_30c24c37-f25a-47ce-be50-8a1aeb905332" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_dei_EntitiesTable_dc0a7a6d-1bce-4b56-9c47-1c17c42ec860" xlink:to="loc_us-gaap_StatementClassOfStockAxis_30c24c37-f25a-47ce-be50-8a1aeb905332" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_30c24c37-f25a-47ce-be50-8a1aeb905332_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_30c24c37-f25a-47ce-be50-8a1aeb905332" xlink:to="loc_us-gaap_ClassOfStockDomain_30c24c37-f25a-47ce-be50-8a1aeb905332_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_d34936f6-70da-45d8-925a-4b8300d11b87" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_30c24c37-f25a-47ce-be50-8a1aeb905332" xlink:to="loc_us-gaap_ClassOfStockDomain_d34936f6-70da-45d8-925a-4b8300d11b87" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_6e90c8d4-b479-4b16-a35e-32630e0e4362" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_d34936f6-70da-45d8-925a-4b8300d11b87" xlink:to="loc_us-gaap_CommonStockMember_6e90c8d4-b479-4b16-a35e-32630e0e4362" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_NotesDue20271.000Member_3a8926e7-fda4-4872-ac67-baad863de932" xlink:href="pfe-20231213.xsd#pfe_NotesDue20271.000Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_d34936f6-70da-45d8-925a-4b8300d11b87" xlink:to="loc_pfe_NotesDue20271.000Member_3a8926e7-fda4-4872-ac67-baad863de932" xlink:type="arc" order="1"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>5
<FILENAME>pfe-20231213_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2023 Workiva-->
<!--r:561d4948-4979-4b6f-ba73-bfebeab2ca2b,g:2bded373-6141-4b85-86a6-c93c11857ae4-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_dei_EntityInformationLineItems_2b18cf41-c009-4dee-9f68-5fb6fefc8442_terseLabel_en-US" xlink:label="lab_dei_EntityInformationLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Information [Line Items]</link:label>
    <link:label id="lab_dei_EntityInformationLineItems_label_en-US" xlink:label="lab_dei_EntityInformationLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Information [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInformationLineItems" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityInformationLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInformationLineItems" xlink:to="lab_dei_EntityInformationLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_NotesDue20271.000Member_31ad7a9e-3cbe-4529-aa21-a9979a069b4b_terseLabel_en-US" xlink:label="lab_pfe_NotesDue20271.000Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Notes Due 2027, 1.000% [Member]</link:label>
    <link:label id="lab_pfe_NotesDue20271.000Member_label_en-US" xlink:label="lab_pfe_NotesDue20271.000Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Notes Due 2027, 1.000% [Member]</link:label>
    <link:label id="lab_pfe_NotesDue20271.000Member_documentation_en-US" xlink:label="lab_pfe_NotesDue20271.000Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Notes Due 2027, 1.000% [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_NotesDue20271.000Member" xlink:href="pfe-20231213.xsd#pfe_NotesDue20271.000Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_NotesDue20271.000Member" xlink:to="lab_pfe_NotesDue20271.000Member" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_3735ca8a-28d3-45c5-857e-01beca5dfb3e_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockMember_9006205d-1b14-42a7-a81e-9abaf97b23bf_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_label_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember" xlink:to="lab_us-gaap_CommonStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_PreCommencementTenderOffer_f73055bd-c82e-4e27-bf57-97640ae36fee_terseLabel_en-US" xlink:label="lab_dei_PreCommencementTenderOffer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
    <link:label id="lab_dei_PreCommencementTenderOffer_label_en-US" xlink:label="lab_dei_PreCommencementTenderOffer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementTenderOffer" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementTenderOffer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_PreCommencementTenderOffer" xlink:to="lab_dei_PreCommencementTenderOffer" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfStockDomain_c6ff98e1-0cc5-436e-a680-250c4595799d_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfStockDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Domain]</link:label>
    <link:label id="lab_us-gaap_ClassOfStockDomain_label_en-US" xlink:label="lab_us-gaap_ClassOfStockDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockDomain" xlink:to="lab_us-gaap_ClassOfStockDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SolicitingMaterial_e8b6149d-3759-4d07-8613-f7c124b14bcc_terseLabel_en-US" xlink:label="lab_dei_SolicitingMaterial" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Soliciting Material</link:label>
    <link:label id="lab_dei_SolicitingMaterial_label_en-US" xlink:label="lab_dei_SolicitingMaterial" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Soliciting Material</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SolicitingMaterial" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SolicitingMaterial"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SolicitingMaterial" xlink:to="lab_dei_SolicitingMaterial" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_0de5d5c0-8859-4bf3-9554-f6da27be4a00_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_49c5a9db-8926-46aa-9178-c2d7d1f26e91_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_91613b50-9a86-4f8a-87c7-471d9f97d31c_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_225b963b-fb6d-49d2-b892-44bec869b841_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_1240314f-7c80-437e-841d-db203d61c79d_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_WrittenCommunications_e0f7bc45-7965-4c29-866a-e11f0abcb003_terseLabel_en-US" xlink:label="lab_dei_WrittenCommunications" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Written Communications</link:label>
    <link:label id="lab_dei_WrittenCommunications_label_en-US" xlink:label="lab_dei_WrittenCommunications" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Written Communications</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_WrittenCommunications" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_WrittenCommunications"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_WrittenCommunications" xlink:to="lab_dei_WrittenCommunications" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_958a6d46-ff83-4079-b582-25698381b074_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_8cbfd9eb-a011-4818-8479-1dbc1f02c2ce_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_6a202f52-e44a-42fb-9c71-294cd5e3ea45_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_2dd6c5cd-6170-4ed5-8a71-0e3a24dba417_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_b524288a-37a0-40e7-a71e-b18d7b505f8b_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_PreCommencementIssuerTenderOffer_c1ebcb03-b3ad-494b-a1f1-ec6f03309728_terseLabel_en-US" xlink:label="lab_dei_PreCommencementIssuerTenderOffer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
    <link:label id="lab_dei_PreCommencementIssuerTenderOffer_label_en-US" xlink:label="lab_dei_PreCommencementIssuerTenderOffer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementIssuerTenderOffer" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementIssuerTenderOffer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_PreCommencementIssuerTenderOffer" xlink:to="lab_dei_PreCommencementIssuerTenderOffer" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_c9c31ce4-4e5c-4828-b969-a300efa91a3f_terseLabel_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_549c4715-f9a4-417e-89b2-49d3fb3f7b33_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_7d621a61-3e63-4b60-a213-7d09c9ab5c8c_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_a1b96497-5d16-4047-a48b-99b2fbfd052a_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementClassOfStockAxis_c15acf1c-8a63-4e2a-85d6-b5cd743e9de7_terseLabel_en-US" xlink:label="lab_us-gaap_StatementClassOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementClassOfStockAxis_label_en-US" xlink:label="lab_us-gaap_StatementClassOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementClassOfStockAxis" xlink:to="lab_us-gaap_StatementClassOfStockAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_6e90448a-4b54-4e21-aa0c-a329665358f0_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntitiesTable_dfa0f92e-8b83-4227-914c-6eaa4d695764_terseLabel_en-US" xlink:label="lab_dei_EntitiesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entities [Table]</link:label>
    <link:label id="lab_dei_EntitiesTable_label_en-US" xlink:label="lab_dei_EntitiesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entities [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitiesTable" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntitiesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitiesTable" xlink:to="lab_dei_EntitiesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_d4924969-ef5c-41a8-93c4-597f5e02b623_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_8b50e049-bd34-4d49-a0ee-4379ffc99aed_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_71010440-4967-4051-b395-93d3ed6f2fb5_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>6
<FILENAME>pfe-20231213_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2023 Workiva-->
<!--r:561d4948-4979-4b6f-ba73-bfebeab2ca2b,g:2bded373-6141-4b85-86a6-c93c11857ae4-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.pfizer.com/role/CoverPage" xlink:type="simple" xlink:href="pfe-20231213.xsd#CoverPage"/>
  <link:presentationLink xlink:role="http://www.pfizer.com/role/CoverPage" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_0f6e7dd8-947f-4efb-ab89-ce747994ac57" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitiesTable_dc0a7a6d-1bce-4b56-9c47-1c17c42ec860" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntitiesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0f6e7dd8-947f-4efb-ab89-ce747994ac57" xlink:to="loc_dei_EntitiesTable_dc0a7a6d-1bce-4b56-9c47-1c17c42ec860" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_30c24c37-f25a-47ce-be50-8a1aeb905332" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntitiesTable_dc0a7a6d-1bce-4b56-9c47-1c17c42ec860" xlink:to="loc_us-gaap_StatementClassOfStockAxis_30c24c37-f25a-47ce-be50-8a1aeb905332" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_d34936f6-70da-45d8-925a-4b8300d11b87" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_30c24c37-f25a-47ce-be50-8a1aeb905332" xlink:to="loc_us-gaap_ClassOfStockDomain_d34936f6-70da-45d8-925a-4b8300d11b87" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_6e90c8d4-b479-4b16-a35e-32630e0e4362" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_d34936f6-70da-45d8-925a-4b8300d11b87" xlink:to="loc_us-gaap_CommonStockMember_6e90c8d4-b479-4b16-a35e-32630e0e4362" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_NotesDue20271.000Member_3a8926e7-fda4-4872-ac67-baad863de932" xlink:href="pfe-20231213.xsd#pfe_NotesDue20271.000Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_d34936f6-70da-45d8-925a-4b8300d11b87" xlink:to="loc_pfe_NotesDue20271.000Member_3a8926e7-fda4-4872-ac67-baad863de932" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInformationLineItems_b2d98124-317f-497a-806d-41db84de2a71" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityInformationLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntitiesTable_dc0a7a6d-1bce-4b56-9c47-1c17c42ec860" xlink:to="loc_dei_EntityInformationLineItems_b2d98124-317f-497a-806d-41db84de2a71" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_6ca4c5e8-d4ae-42e6-bb38-cd58a5df464b" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_b2d98124-317f-497a-806d-41db84de2a71" xlink:to="loc_dei_Security12bTitle_6ca4c5e8-d4ae-42e6-bb38-cd58a5df464b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_2b02f45d-f9fc-4036-b185-3c0b6b07f9c5" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_b2d98124-317f-497a-806d-41db84de2a71" xlink:to="loc_dei_DocumentType_2b02f45d-f9fc-4036-b185-3c0b6b07f9c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_a43b0c24-576b-4c6e-89eb-ca651f115e71" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_b2d98124-317f-497a-806d-41db84de2a71" xlink:to="loc_dei_DocumentPeriodEndDate_a43b0c24-576b-4c6e-89eb-ca651f115e71" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_28d1a50c-544f-4ac8-bb10-6aa2ed247976" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_b2d98124-317f-497a-806d-41db84de2a71" xlink:to="loc_dei_EntityRegistrantName_28d1a50c-544f-4ac8-bb10-6aa2ed247976" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_004d5800-7160-40f7-9b5e-9f4018a2ac00" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_b2d98124-317f-497a-806d-41db84de2a71" xlink:to="loc_dei_EntityIncorporationStateCountryCode_004d5800-7160-40f7-9b5e-9f4018a2ac00" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_97d61ff7-39bb-48e0-87f2-134f361ba640" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_b2d98124-317f-497a-806d-41db84de2a71" xlink:to="loc_dei_EntityFileNumber_97d61ff7-39bb-48e0-87f2-134f361ba640" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_51cb6063-fa5c-44dc-9659-5950ea3cb85e" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_b2d98124-317f-497a-806d-41db84de2a71" xlink:to="loc_dei_EntityTaxIdentificationNumber_51cb6063-fa5c-44dc-9659-5950ea3cb85e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_ab51c8f6-3faa-4944-97a6-6e129f2b9fd7" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_b2d98124-317f-497a-806d-41db84de2a71" xlink:to="loc_dei_EntityAddressAddressLine1_ab51c8f6-3faa-4944-97a6-6e129f2b9fd7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_4237bb69-39f6-4746-a4ac-4e885a8dd4e8" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_b2d98124-317f-497a-806d-41db84de2a71" xlink:to="loc_dei_EntityAddressCityOrTown_4237bb69-39f6-4746-a4ac-4e885a8dd4e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_78c83c61-2a2b-4c07-bb54-7e784b370519" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_b2d98124-317f-497a-806d-41db84de2a71" xlink:to="loc_dei_EntityAddressStateOrProvince_78c83c61-2a2b-4c07-bb54-7e784b370519" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_fb183b6d-1ba3-40e2-8743-5cce02dabe8a" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_b2d98124-317f-497a-806d-41db84de2a71" xlink:to="loc_dei_EntityAddressPostalZipCode_fb183b6d-1ba3-40e2-8743-5cce02dabe8a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_dea86abb-8735-42e7-b779-ade7452a0590" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_b2d98124-317f-497a-806d-41db84de2a71" xlink:to="loc_dei_CityAreaCode_dea86abb-8735-42e7-b779-ade7452a0590" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_a542bd1f-7237-449a-97c5-56ec0c1de846" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_b2d98124-317f-497a-806d-41db84de2a71" xlink:to="loc_dei_LocalPhoneNumber_a542bd1f-7237-449a-97c5-56ec0c1de846" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_WrittenCommunications_a9a67409-f0a7-474b-a5fd-2d0a67fb2429" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_WrittenCommunications"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_b2d98124-317f-497a-806d-41db84de2a71" xlink:to="loc_dei_WrittenCommunications_a9a67409-f0a7-474b-a5fd-2d0a67fb2429" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SolicitingMaterial_6beb3048-b09c-4791-87f9-a14164c893a4" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SolicitingMaterial"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_b2d98124-317f-497a-806d-41db84de2a71" xlink:to="loc_dei_SolicitingMaterial_6beb3048-b09c-4791-87f9-a14164c893a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementTenderOffer_406e3778-0db3-4e21-9d0c-4b2d1ed26d23" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementTenderOffer"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_b2d98124-317f-497a-806d-41db84de2a71" xlink:to="loc_dei_PreCommencementTenderOffer_406e3778-0db3-4e21-9d0c-4b2d1ed26d23" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementIssuerTenderOffer_b6417c19-3ca8-4f85-bcff-4abd4dc1cd40" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementIssuerTenderOffer"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_b2d98124-317f-497a-806d-41db84de2a71" xlink:to="loc_dei_PreCommencementIssuerTenderOffer_b6417c19-3ca8-4f85-bcff-4abd4dc1cd40" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_b8c81146-773b-49c4-9fd3-f040607314f1" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_b2d98124-317f-497a-806d-41db84de2a71" xlink:to="loc_dei_EntityEmergingGrowthCompany_b8c81146-773b-49c4-9fd3-f040607314f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_ffa42d0a-d4ec-460f-aee9-af22d51d361a" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_b2d98124-317f-497a-806d-41db84de2a71" xlink:to="loc_dei_AmendmentFlag_ffa42d0a-d4ec-460f-aee9-af22d51d361a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_dd2b3128-008a-4ce3-a1c5-c8884a1728ec" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_b2d98124-317f-497a-806d-41db84de2a71" xlink:to="loc_dei_EntityCentralIndexKey_dd2b3128-008a-4ce3-a1c5-c8884a1728ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_31a8b980-62f9-473c-a079-d7a6cf815433" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_b2d98124-317f-497a-806d-41db84de2a71" xlink:to="loc_dei_TradingSymbol_31a8b980-62f9-473c-a079-d7a6cf815433" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_7b8a6f00-8012-42d5-a343-7dbcdfacb735" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_b2d98124-317f-497a-806d-41db84de2a71" xlink:to="loc_dei_SecurityExchangeName_7b8a6f00-8012-42d5-a343-7dbcdfacb735" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>pfizerlogoaa.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 pfizerlogoaa.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_X1"B17AI9@  34T *@    @ ! $[  (
M   0   (2H=I  0    !   (6IR=  $    @   0>NH<  <   @,    /@
M   <Z@    @
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                                                 %)O<V5N+"!0
M96YN>2!3+@   >H<  <   @,   (;      <Z@    @
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M!0$! 0$! 0           0(#! 4&!P@)"@O_Q "U$  " 0,# @0#!04$!
M 7T! @, !!$%$B$Q008346$'(G$4,H&1H0@C0K'!%5+1\"0S8G*""0H6%Q@9
M&B4F)R@I*C0U-C<X.3I#1$5&1TA)2E-455976%E:8V1E9F=H:6IS='5V=WAY
M>H.$A8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*
MTM/4U=;7V-G:X>+CY.7FY^CIZO'R\_3U]O?X^?K_Q  ? 0 # 0$! 0$! 0$!
M         0(#! 4&!P@)"@O_Q "U$0 " 0($! ,$!P4$!  ! G<  0(#$00%
M(3$&$D%1!V%Q$R(R@0@40I&AL<$)(S-2\!5B<M$*%B0TX27Q%Q@9&B8G*"DJ
M-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U=G=X>7J"@X2%AH>(
MB8J2DY25EI>8F9JBHZ2EIJ>HJ:JRL[2UMK>XN;K"P\3%QL?(R<K2T]35UM?8
MV=KBX^3EYN?HZ>KR\_3U]O?X^?K_V@ , P$  A$#$0 _ /I&BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "HY[B&UA,MU-'#&O5Y&"J/Q-25P'Q
M;U$V^@6UBI^:ZFW-_NJ,_P R*Z<)0>)KQI+J<N,Q"PU"59]#M8]3L)?]5>V[
M_P"[*I_K5E75QE&##U!S7S%3XY9(7W1.R-ZJ<&OI9<.+I4_#_@GS$>)7]JE^
M/_ /INBOG6+Q+KD  BUB^4#H/M#8'ZUH6WQ \3VV-NJ/(/25%?/XD9KFEP]7
M7PS3^\ZH\28=_%!K[G_D>]45XS!\6-?BQYL5G,.^Z-@3^35LVWQB7 %WH[ ]
MVBGS^A']:XYY)C8;1OZ-?J=E//,#/>37JG^ESTVBN*L_BIX>N/\ CX^TVI_Z
M:19'_CI-;EEXNT#4!_HVK6Q/]UWV-^38-<-3!8FE\<&OD=]/'86K\%1/YFS1
M34D25 T;JZGH5.0:=7(=@4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 5XK\4M1^V>+S;J^4M(ECQV#'YC_ #'Y5[1)
M(L43R2'"HI9CZ 5\W:I>G4M7N[U@0;B9I,'L"<@5])P_1YJ\JK^ROS/F>(JW
M+0C27VG^"*E%%%?:GPP4444 %%%% !1110!8M;^[L7WV5U-;L>IBD*Y_*M^Q
M^(7B2QP!?FX0?PW"!_UZ_K7,45C4P]&K_$BGZHWI8BM1_AS:]&>E6'Q@N$4+
MJ>F1RGN\#E/T.?YUTMA\3?#EX%$T\MHYXQ/&<?FN17B%%>75R3!U-DX^C_SN
M>K1SW&T]VI>J_P K'TK::C97Z[K&[@N%]8I W\JLU\R12R02"2&1HW7D,C8(
M_&NATWQ]XBTP!4OVN$_N7(\S]3S^M>16X=J+6E-/UT/8H\24WI6@UZ:_Y'O5
M%>9:9\7T.Q-7TYE_O26S9_\ '3_C78:7XST'5^+748EDZ>7,?+;\ >OX5XU?
M+L50^.#MWW7X'MT,RPF(TA-7[/1_B;M% (/3FBN ] **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@#G?'FHG3/!E](AQ)*GDK_P "X/Z9->!UZC\7
M]1'EZ?IJMR2T[KZ#[J_^S5Y=7WF14?9X3G>\G?\ 0_/\_K>TQ?(MHJWZA111
M7NG@!1110 4444 %%%% !1110 4444 %%%% !1110!KZ7XHUK1F'V#4)D0<>
M6QW)_P!\GBNTTGXNRKM36K ..\ML<'_OD_XUYI17#B,OPV(_B05^^S._#YAB
ML-_#F[=MT?0>D>+]$UL 65]'YI./*D^1\_0]?PK;KYBKH-'\<:]HN%@O&GA!
M_P!5<?.OX9Y'X&O Q'#SWH2^3_S_ . ?18;B-;8B'S7^7_!/?:*X'1OBOIMW
MMCU>%[&0G&]?GC/]1^5=O:7MM?P":RN(YXCT>-@P_2OG<1A*^&=JL6OR^\^D
MP^,H8E7I23_/[B>BBBN4Z@HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***KZA=K8:;<W<GW8
M(FD/X#--)R=D*345=GA_Q!U'^T?&MX5.4MR(%_X#U_7-<S4DTTEQ/)-,VZ21
MB[L>Y)R34=?J5"DJ-*--=$D?D]>JZU651]6V%%%%;&(4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 5;T_5+[2K@3Z==2V\@.<HV ?J.A_&
MJE%*45)6DKHJ,I1?-%V9Z5H7Q9E3;#K]L)%Z&X@&&_%>A_#'TKT72M<T[6K?
MS=,NXYUQR%/S+]1U%?.%36MW<65PL]G-)!*O1XV*D5X.*R.A5]ZE[K_#[CZ#
M"9]B*/NU?>7X_?\ YGTQ17D_A_XK7,!2#Q!#]HCZ?:(@ X^J]#^E>EZ7K%AK
M-J+C3+F.=.^T\K[$=17R>*P&(PC_ 'D=._0^NPF88?%K]W+7L]R[1117"=X4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M\%BH?%3?W,Q**FFM;BW8K<021,.H=",5#72FGJCE::T84444Q!1110 4444
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MEC*?/3^:["T445Q'<%%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M=-*HW[K/9****^(.D**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M75VV;JYFG/K)(6_G4%%>C"C2I_!%+T1YLZU6I\<F_5A1116ID%%%% !1110
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MHHH **** "BBB@ HHHH **** .T^%VG&\\7BX(REG$TASZGY1_,_E7M5>?\
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M]_$!.NK1/_O6L?\ 05B^%<:MI1^]_P"0_;Q/L&BOD5?VA/'PZWMH?K:K2_\
M#0OCW_G[L_\ P%6H_P!5\=WC][_R'[:)]<T5\@O\?_'[CC4K=?\ =M4_PJI+
M\<OB%+_S'V0>B6T0_P#9:I<+8U[RC][_ ,A>VB?9-%?%$_Q;\>7 (D\3WP!_
MN,$_D!6-=^,/$E]G[7KVI2@]0UT^/RS6\.$\0_BJ)?>_\A>W78^Y[K4K&Q4M
M>WD%N!U,LH7^=<QJ/Q8\#:6&^T>);%V7JD#^:?\ QW-?%4L\TQS-*\A]78FH
MZ[J7"=)?Q*K?HK?YDNN^B/J;5_VE?"EFK+I5G?Z@XZ'8(D/XDY_2O/=<_:4\
M47ZM'HUE9Z6IZ/@S./Q/'Z5XW17KT,@R^CKR<S\]?PV_ S=6;-C7/%FO^)9C
M+KFK75Z?[LDAVCZ*.!^58]%%>W"$:<>6"LO(SW.X\#:R75M,G;)4%H2?3N/Z
MUW-K;O>7D-M$,O,X11[DXKQ:PNWL;^&YC^]$X;Z^U?17PSLUU;Q=93 9BA3[
M3G\/E_4BO*S"2P].5;LFSY7,,#?&0Y-IO\>I[C9VRV=C!;1C"PQJ@^@&*FHH
MK\D;;=V?=I)*R"BBBD,**** "O,/V@==_LCX6W%LC[9=2E2V7'=<[F_1<?C7
MI]?-'[3FO?:?$FEZ'&WRV<!GD'^TYP/T7]:]G(\/[?'TT]EK]W_!,ZCM%GAM
M%%%?K1PA115C3[*74=2MK*W&9;F58D [EC@?SI-I*[ ^M?@%H7]C_"NTGD3;
M-J$CW+<<D$X7] #^->F54TG3X]*T6RT^$ 1VL"0KCT50/Z5;K\6Q==XC$3JO
M[3;/1BK*P4445S#"BBL?Q9X@@\+^%-0UFZ("6L)< _Q-T5?Q.!5PA*<E".[#
M8^0OB]?+J'Q:U^9&W*MSY0(_V%"_S!KBZFN[J6]O9KJX;=+/(TCL>Y)R:AK]
MJP]+V-&%/LDON1YS=W<****V$=;\+=/.I_%+P_;J,XO$E/L$^;^E?;E?+?[-
M>@M?>.[K6'7]UIML0IQ_')P/T#5]25^;<45E/&*FOLK\7K_D==%6C<^?_P!I
M_7=MKHV@Q/\ ZQFNI5![#Y5_FU?.U>@?&[71KOQ6U-HVW0V96T3G^X,-_P"/
M;J\_K[/)L/\ 5\#3@]VKOYZG/4=Y,****]8@MZ3!;W6L6<%].MO;23HLTS=$
M0D9/X"OLB#XL?#ZWMXX8O$UBJ1H$4 MP ,#M7Q917CYEE-/,7'VDFN6^UNII
M"HX;'VM_PM[P#_T-%E^;?X4?\+>\ _\ 0T67YM_A7Q317D_ZJ87^>7X?Y%^W
MEV/M;_A;W@'_ *&BR_-O\*/^%O> ?^AHLOS;_"OBFBC_ %4PO\\OP_R#V\NQ
M]K?\+>\ _P#0T67YM_A1_P +>\ _]#19?FW^%?%-%'^JF%_GE^'^0>WEV/M;
M_A;W@'_H:++\V_PJQ8_$_P %ZG?PV5AXAM)[F=PD42;B78] .*^(:]4_9YT/
M^U/BA'>.FZ'38'G)QT8C:O\ ,G\*Y<9PYA,-AYUG.7NJ_3_(J-:3=CZUK%\0
M>+] \*F >(=4@L#<9\KS2?GQC.,#W%;5?*7[1VMG4?B2FGJV8]-M4CP#_$_S
MG]"OY5\UE. 6/Q*HR=E9MV_KN;5)<L;GO7_"WO /_0T67YM_A1_PM[P#_P!#
M19?FW^%?%-%?7_ZJ87^>7X?Y'/[>78^UO^%O> ?^AHLOS;_"C_A;W@'_ *&B
MR_-O\*^*:*/]5,+_ #R_#_(/;R['VM_PM[P#_P!#19?FW^%'_"WO /\ T-%E
M^;?X5\4T4?ZJ87^>7X?Y![>78^UO^%O> ?\ H:++\V_PH_X6]X!_Z&BR_-O\
M*^*:*/\ 53"_SR_#_(/;R['VM_PM[P#_ -#19?FW^%'_  M[P#_T-%E^;?X5
M\4T4?ZJ87^>7X?Y![>78^UO^%O> ?^AHLOS;_"NJT[4;35M.AOM.F$]K.NZ*
M0 @./49[5\F?!KX82>.==%]J<;+HEDX,IQCSW'(C'MZ^WUKZZBBC@A2*%%2-
M%"JJC 4#H *^5S?!X7!5%1HR<I=;VT\MMS>G*4E=CJ*.E>/_ !'^/>F>&7ET
MSPRL>J:FN5>7.883Z$C[Q]A^=>=A<'7Q=3V=&-W^7J5*2BKL]8OM0L]+LWNM
M1NH;6WC&6EF<(H_$UYIKW[0G@O1W:*REN-6E7_GUCPG_ 'TV/TS7S'XD\7Z[
MXMOC=:_J,UVV?E1CA$]E4<"L6OM\)PK2BKXF5WV6B_S_ ".>5=]#W^]_:CN3
M(1IWAF()V:>Z)/Y!?ZU47]J+60WS^';$CT$[BO"Z*]A9#EJ5O9?B_P#,S]K/
MN?1FF_M16CL!J_AR:(=VMK@/C\"!7?\ AWXU>"/$;K%%JHL9V.!%?+Y1)],_
M=/YU\:45R5^&L#47N)Q?D_\ .Y2K26Y^A"LKH&1@RL,@@Y!%+7Q?X%^+/B3P
M-<(EM<M>:=GY[&X8E,?[)ZJ?IQ[5]6>"/'6C^/-$&H:/+AUP)[9S^\A;T(_D
M>AKXS,LFQ&7^\_>AW7Z]CHA44CI****\0T"BBH;NZBL;*>[N6V0P1M)(WHJC
M)/Y"FDV[(#G-2^)G@W1]2FL-2\0VEO=0-MEB8G*'T.!57_A;W@'_ *&BR_-O
M\*^-];U)]9U^_P!3F^_>7,D[>Q9B?ZU1K]!APIAW%<TY7Z[?Y'+[=GVM_P +
M>\ _]#19?FW^%'_"WO /_0T67YM_A7Q315_ZJ87^>7X?Y"]O+L?=.A>._#'B
M:^:ST'6;>^N$C,C1Q9R%! SR/4BN@KP#]E[1%6RUO773YGD2SB;'0 ;V_/<G
MY5Z#\2OBQI/P^M/).+W5Y%S#9JWW?1G/\(_4U\EC,NY<<\)A;R:_IF\9^[S2
M.XN[RVT^U>YOKB.W@C&7EE<*JCW)KSC6_C]X&T>1HH;R?4Y%_P"?*+<O_?1(
M'Y5\S>+?'GB#QK?&XUR^>1,YCMD.V*,>@7^IYKG*^GPG"M-1YL3*[[+;[_\
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MAQM%%%??G*=K\']6_L?XL:%.6PDUQ]F;W\P%!^I%?:E?!?A:0Q>,-&D7JE_
MP_"1:^]*_/N+*:5>G/NK?<_^"=5!Z,*^,?C/KHU_XK:O+&28K5Q:1Y/:,;3^
M;;C^-?7VOZHFB>'-1U23&VSMI)^3UVJ3C]*^"[FXDN[J6XG8O+,Y=V/4DG)-
M5PIA[U:E=]%;[_\ A@KO1(BHHHK[\Y0HHKN_A#X&_P"$X\=06]U&6TVS N+P
MXX90>$S_ +1X^F:QQ%>&'I2JU-DKC2;=D>M? +X7)IUC%XNUV &\N%S81./]
M2A_Y:8_O'MZ#ZU[I2(BQQJD:A54850, "EK\?QV,J8VNZU3KMY+L=\8J*LB"
M^LK?4=/N+*]C66WN(VBE1APRL,$?E7Q%X^\&WG@;Q;=:3=JQA#%[68CB:(GY
M6^O8^X-?<E87BOP9H?C73!9>(+-9U7)CD!VR1'U5NU>ADV:O+JKYE>$M_P#,
MBI#G1\)T5]*W/[+^CO<%K3Q!>Q19^Y)$KD#Z\?RKIO"OP$\(>&[I+NXCEU:Y
MC.5:\(**?4(!C\\U]E4XEP$8<T6V^UO\S!49'&_L]_#.XM)QXQUR Q$H4T^%
MQAL$8,I'N#@?4GTKZ H P,#@"BOS['XVICJ[K5/DNR['5&*BK(****X2@HHH
MH *\9_::U#R/A_I]D#AKK4%8^ZHC9_4K7LU>(_M/V;R>#='O5^Y!?&-O^!H2
M/_0*]?)5%YC2YN_Z&=3X&?,E%%%?KAPA1110 4444 %*K,C!D)5E.00<$&DH
MH ]A\ ?M ZSX>\NQ\3J^KZ>,*)2?W\8_WC]X>QY]Z^C/#'C+0O&%@+O0-0CN
M5Q\\><21^S*>17PE5O3-5O\ 1;]+W2;R:SN8S\LL+E6'Y5\UF'#N'Q5YTO<E
M^#^7^1M"JX[GW]17SGX(_:2G@$=GXWM?/3@"^M5PP]V3H?J,?2O=]!\3:-XG
ML%O-!U""]A(Y\MOF7V9>H/UKX+&Y9BL$_P!]'3NMOO.F,XRV-6BBBO.+"BBB
M@ HHHH *R_$VKQZ!X6U+59CA;.V>7ZD*<#\\5J5Y-^T7KW]E_#3^SXS^\U2Y
M2$\]$7YV/_CH'XUV8&A]9Q,*/=K[NOX$R=HMGRE+*\\SRS,7DD8LS$Y)).2:
M9117[/L>>%%%% !1110 4444 %%%% !1110 4444 %%%% !1172>$O 'B+QK
M>"'0[!Y(L_/<R#;$GU8_R'-9U*L*47.H[)=6"3>QSJ(TDBI&I=V.%51DD^E?
M1OP9^"C:?)!XE\7VX%R,/:6+C_5GL[CU]!V[UUWPY^"NB^"!'?7VW4]8'/VA
MU^2$_P"PO;ZGGZ5Z97P6<<0^VBZ&%TCU??T\CJITK:R"BBBOC3H"BBB@ HHH
MH *9-*L$$DLAPD:EF)[ #-/KBOB[KG_"/_"W6;E'VS2P_9XN?XG.W^1)_"MJ
M%)UJL:4=Y-+[Q-V5SY!\4ZRWB'Q9JFKMG_3+EY5SV4G@?EBLFBBOVN$%"*C'
M9'G!1115 :^@>%-<\4RS1^']-GOW@4-((A]P'IFMS_A47CW_ *%B^_[Y'^->
MX?LU:']A\"WFK.N)-1N2%./X(^!^I:O9J^)S#B2MAL5.C2BFHNVM_GU[G1&B
MG&[/BG_A47CW_H6+[_OD?XT?\*B\>_\ 0L7W_?(_QK[6HKA_UKQ7\D?Q_P R
M_81[GQ3_ ,*B\>_]"Q>_D/\ &K=M\$?B!=, /#\D8]99HTQ^;5]ET5+XKQ=M
M(1_'_,/81/EK2OV:?%5W@ZG?Z?8+W 9I6'X  ?K7H?A[]F_POIA276KFYU:5
M>2A/E1G\!S^M>Q45YU?/\PKJW/RKRT_'?\2U2@BCI.B:9H-F+31K"WLH!_RS
M@C"@_7'6KU%%>+*3D[R=V:!1114@<W\0M=7PY\/M9U,MM>*U98_]]OE7]2*^
M&B222>2:^G?VF=<^R>#].T:-OFO[DR.,_P $8_Q8?E7S%7Z3POA_9X-U7O)_
M@M/SN<=9WE8****^J,0KZ\^ .A?V/\++6X=-LVHRO<O[@G:OZ*#^-?)>GV4N
MI:E;65N,RW,JQ(/=C@?SK[UTC3X])T6RT^  1VL"0J!Z*H']*^.XJQ'+0A17
MVG?[O^'.B@M;ERBBBOSTZ@K"\;:T/#O@?5]5SAK:U=D_WB,+^I%;M>-_M*:Z
M;#P':Z5$^'U*Z&\ ]40;C^NVN[+\/]9Q=.EW?X=?P)F[1;/EMF+L68Y+'))[
MTE%%?LIYX445)!"]Q<1PQ#=)(X11ZDG HV ^K?V==#_LSX9_;I$VRZE<O+DC
MDHORK_(G\:]8K+\,Z0F@^%=,TJ/I9VR1'W(49/YYK4K\8QU?ZQB9U>[?W=#T
M(JT4@HHHKC*"N3^(OCRR\ >%Y=1N2LEW)E+2W)YEDQ_Z".I-;NN:U8^'=%N=
M5U680VMLA=V/?V'J3T KXN^(/CF^\>^*)=3O"4MUREK;YXBCSP/J>I/K7OY+
ME3Q];FG\$=_/R_S,JD^5>9AZQJ][KVL7.IZI.T]U<N7D=O7T^@Z8JE117ZG&
M*BE&.R.(***W/!_A/4/&GB6VT?2T)>4YDD(^6)!U9O8?SXJ:E2-.#G-V2!:G
M2_"3X;3^/_$8:Y5H]'LV#74O3?Z1J?4]_0?A7V':VL%C:16MG$D,$*!(XT&%
M50,  5E^%/"^G^#_  [;:/I,>V&%?F<CYI&[LWJ36S7Y1F^9RS"O=:06R_7U
M9W4X<B"FR.L4;22'"J"S'T IU8OC*[^P^!=<N@<&+3YV4^_EG'ZUY-.//-17
M4T9\3^*]8?7_ !=JFJR$YN[J20 GHI8X'X#%9%%%?MT(*$5&.R/-W"BBGQ1/
M/,D4*%Y)&"HJC)8G@"J 9173?\*W\9_]"SJ7_@.U+_PK?QG_ -"SJ7_@.U<_
MUK#_ ,Z^]#Y7V.8HKI_^%;^,_P#H6=2_\!VH_P"%;^,_^A9U+_P':CZUA_YU
M]Z#E?8YBBNG_ .%;^,_^A9U+_P !VH_X5OXS_P"A9U+_ ,!VH^M8?^=?>@Y7
MV.8HKI_^%;^,_P#H6=2_\!VH_P"%;^,_^A9U+_P':CZUA_YU]Z#E?8J^![1K
M[Q_H-L@R9-1@!^GF D_EFONROECX,?#SQ#:?%'3[[6=%N[.ULUDF,EQ$54MM
M*J.>^6'Y5]3U\!Q1B(5<3",'=)=/-_\  .JBFD>5_M#ZV-+^%TEDC[9=3N$@
M !Y*@[V/T^4#\:^2J]N_::UW[7XNTW18S\EA;&9_]^0]/^^57\Z\1KZCA[#^
MQP$6]Y7?^7X(QJN\PHHHKWS(*^O_ (%>$!X7^'5O<SQE+[5<74V>H4C]VO\
MWSS]6-?+_@;P_P#\)3XYTG1BK-'=7"B;;U$8^9S_ -\@U]T1QK%$L<:A410J
MJ.@ KXOBK%N,(8:/75^G3\?R.BA'6XZBBBO@#J"BBB@ HHHH **** "BBB@
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M2U7:UO:H)!_MD9;]2:WJ**_$ZDW4FYRW;N>BM$%%%%0,**** "BBB@ HHHH
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M#L4?3Y2?QKU6OR;/<1[?,*CZ+3[O^#<[J2M!!1117BF@4444 %%%% !1110
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MU;3M7@\[2KZVO(_[]O*KC]#5NO'<7%V9H%%%%( HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH IZOJ$6DZ+>:A.=L=K \K$^B@FO@J
M_O9=1U*YO;EMTUQ*TKGU+')_G7UK\?=>&C?"N[@5MLNI2+:ICT)W-_XZI_.O
MD*OT+A7#\M"=9_:=ODO^'.2N];!1117V)@%>Y?LQZ%]I\2:KK<B_+9P"",_[
M3G)_1?UKPVOKO]G_ $/^R/A7;7$B;9M1F>Y8XY*YVK^BY_&OG^(L1[' 22WE
M9?Y_@C6DKR/3J***_+#M"BBB@ HHHH **** "BBB@ K@?C7KIT'X4ZH\;[9K
MM1:Q\]=YP?\ QW=7?5\\?M/Z\&FT;08VY0-=RC/K\J_R:O5R?#_6,=3ATO=_
M+4BH[19\^T445^O' %%%;'A+1F\0^,-*TE5W"ZNDC;_=S\Q_+-3.:A%SELM0
MW/K[X2Z#_P ([\+]&M'7;+)#]HE_WI/F_D0/PKLZ;%&L,*11C"(H51Z 4ZOQ
M2O5=:K*K+>3;^\]%*RL%%%%8C..^+&N?\(_\+]:NU?9*\!@B]V?Y?Y$G\*^)
MZ^D/VGM<\K2-'T.-OFGE:YD'^RHVK^K'\J^;Z_3.&</[+!>T>\G?Y+3_ #..
ML[RL%%%%?3F(5]C? W0_[$^$^F[UQ+?;KM^.N\_+_P".A:^1=(T^35M:LM/A
M!,EU.D*@>K,!_6OO6PLXM.TZWL[=0L5O$L2 =@HP/Y5\9Q7B.6C3H+J[_=_P
MYT4%JV6***Y[QOXRT_P/X8GU;4FR5&V"$'YII#T4?U/85\'3ISJS4(*[>QTM
MV5V<O\8OB;%X$\/FUT^16UJ]4B!>ODKT,A_IZGZ5\A3327$\DT[M)+(Q9W8Y
M+$\DDUH^)/$6H>*O$%UJ^K2F6XN'R?1!V4>@ XK+K]8RG+89?0Y=Y/=_IZ(X
M:D^=A1117KD!7LOP*^%I\2:DOB37(/\ B56C_N(G'%S(/YJ/U/'K7'?#'X?W
M'C[Q.ELQ:'3;<A[RXZ;5_NC_ &C_ (FOLK3K.QTG38+#3TB@MK=!''&F % K
MY/B#-OJ\/JU%^^]WV7^;-Z5.[NRV  ,#@"BF^;'_ 'U_.CS8_P"^OYU^<ZG6
M.HIOFQ_WU_.CS8_[Z_G19@.HIHD0G =2?K3J0'P_\2O#S>&/B+K&FE-D0N&E
MA';RW^9?T./PKEJ^E_VC_ [:CI%OXJT^'=/8CRKL*.6B)^5O^ DG\#[5\T5^
MO93C%C,'"IU6C]5_5S@J1Y96"BBBO5(/JG]G?QE'K/@LZ!<RC[;I)PBLW+PD
MY4CZ'*^W%>P5\&>&?$NI>$O$%OK&C3>7<P'H>5=>ZL.X-?6G@+XP>'/&MK'&
M;F/3]4P!)9W#A<M_L$\,/U]J_.,^RBI1K2Q-)7A+5VZ/K\CKI5$U9G?T445\
MF;A145S=6]G T]W/'!$HRTDKA5'XFO-/%_Q\\)^'(Y(=,F.M7J\".U/[L'WD
MZ?EFNG#X2OB9<M&+8G)+<]/9E7&Y@N3@9/>EKXN\2?%OQ1XF\16FIW5WY$=E
M.L]M:0$K'&5.1Q_$?<U]@>'M:M_$7AVPU>SSY-Y LJ@]5R.0?<'BO0S'**V7
MTX3J._-VZ/L1"HIO0T:\7_:8UPV7@FPTB,X;4;K>_ND8SC_OIE_*O:*^3OVB
M]<_M/XG&QCDW1:9;)#@'@.WSM^/S ?A6W#^']MF$6]HZ_=M^-A57:!Y/1117
MZH<05);P2W5S%;VZ&269PB(.K,3@#\ZCKN_@QH7]O?%?2(F&8K5S=R?2,9'_
M (]M'XUAB*RH4957]E-_<-*[L?7OA_2H]#\-Z=I<( 2SMHX1COM4#-:-%%?B
MLI.4G)[L]$****D HHHH **** "BBB@ HHHH **** "BBB@ HHHH X#XG?"G
M3/B#I_G+ML]8A3$%V!][_8?U7]1V]*^2O$?AK5?"FLRZ9KEH]M<QGC/W7'9E
M/<'UK[TKGO&/@C1?'&D-8:Y;!\9,4Z<20MZJ?Z=#7TN49[4P5J57WJ?XKT_R
M,:E)2U6Y\+T5WGQ#^$VN^ ;EYI$-[I);$=]$O ] X_A/Z'UK@Z_2*&(I8BFJ
ME*5TSD::=F%%%%;""BBB@ HHHH **** "BBB@ HHHH **** "BBB@"Q:7]YI
M\PEL+J:VD'1X9"A'XBNYT3XW^.]%58UU@WL2_P %Z@E_\>/S?K7GU%85L+0K
MJU6"EZH:DUL?0.C_ +4,H*IK_AY&'\4MG,1_XZV?YUWVD?'WP'JC!9=0FT]S
MVO("H_-<C]:^0**\.OPW@*NL4X^C_P [FBK21][:7XET/6@/[(U>RO2>0()U
M<_D#FM.OSX21XFW1NR,.ZG!KH=*^(7B[12O]F^(=0B5>B&<NO_?+9%>/6X3E
M_P NJOWK]5_D:*OW1]S45\EZ9^T3XYL6'VN6RU!1VGMPN?Q3%=9I_P"U'*,#
M5?#2'U:VN2/T8'^=>35X;S"GM%2]'_G8T5:#/HBBO(K']I+P7<A1=PZE9L>N
M^!64?BK'^5=+8_&7P#?@>7XCMHF/\-PK1X_%@!^M>;4RS&T_BI2^XI3B^IW%
M%8]GXO\ #FH$"QU[39R>@2Z0D_AFM=6#J&4A@>A!ZUQ2A.#M)6+%HHHJ "BB
MB@ HHHH **** "BBB@ HHH/ H ^:_P!IW7?/U[2=#C;Y;:%KB0?[3G _1?UK
MPJNM^*6N?\)#\3=;OE??$+@PQ'_83Y1C\L_C7)5^Q97A_J^"IT^MM?5ZLX)N
M\FPHHHKT2">RM9+_ %"WM(!F2XE6) .Y8X'\Z^]=%TV/1M"L=-AQY=I;I"N/
M]E0/Z5\B? _0AKOQ6TP2)NAL]UV_']P?+_X\17V17Y_Q7B.:K3H+HK_?_P ,
M=5!:-A1117QAT!1110 4444 %%%% !1110 5\7_&37?[?^*NKS*VZ*VD^RQD
M'C$?!_7-?7GB75H]!\+ZEJDIPMI;/*/J!P/SQ7P=/-)<W$D\S;I)&+NQ[DG)
MK[7A3#WJ5*[Z*WWZLYZ[T2(Z***^^.4*]?\ V;]".H?$2;4W3,6FVS,"1T=_
ME'Z;J\@KZG_9LT/[!\/[C5'7$FI7)()'\"?*/UW5X>?XCV&7SMO+3[]_PN:4
ME>9[%1117Y0=P4456U*^BTS2[J^N3MBMH6E<^RC)_E32;=D!\D?'G73K7Q6O
MHE;=%IR+:)[$#+?^/,:\VJUJE_+JFK7=_.=TES,\K$^K$G^M5:_:<)06'P\*
M2^RDCSI.[N%%%%=(CTSX!:$=8^*EI.Z[H=.C>Y?COC:OZMG\*^O:\)_9BT'R
M-!U;79%^:ZF6VC)_NH,G]6_2O=B<#)X%?EO$6(]MCY16T4E^K_%G;15HE;4=
M1M=)TVXO]0F6"VMT,DLCG 4"OC3XG_$*Z^('B=[DEH].MR4L[<G[J_WB/[QZ
MG\JZ_P".OQ2_X274F\.:'-G2K1_W\J'BYD'\U';U//I7C=?3</Y1]7A]9K+W
MWMY+_-F-6I=V04445]88!1110 ])9(\^7(R9Z[6(IWVJX_Y[R?\ ?9J*BBR
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M %(RAE*GH1@TM% '"M\%OA^[%F\.0EB<DF:7G_QZD_X4I\/?^A;A_P"_TO\
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M_O\ 2_\ Q5=W11_:&,_Y^R_\"?\ F'+'L9^AZ#IGAK28]-T2T6TLXR66)22
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M+_\ %5W=%']H8S_G[+_P)_YARQ['"?\ "E/A[_T+</\ W^E_^*H_X4I\/?\
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MU&*V04445QE&3XB\+Z/XLT]+'Q!9K>6R2"58V=E 8 @'Y2.Q-<U_PI3X>_\
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ME!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%>%_M.Z[]G\/:3HD3X:ZG,\JC^Z@P/U;]*]TKY"^/NN_VQ\5+N!&S%IL:VJ_
M4?,WZL1^%?0\.X?VV/C)[1N_T7XLRJNT3S.BBBOU(X@JUI=A)JFKV=A "9+J
M=(5QZLP']:JUZ5\!-"&L_%6SED3=#I\;W3<< @87_P >(_*N;%UUA\/.J_LI
ML<5=V/K;3;&/3-*M;& 8BMH4B0#T4 #^56:**_%FVW=GHA1112 **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** ,+7?!'AKQ-DZYHMG=OC E>("0#V<<C\Z\TU[]FCPW>J[Z#J%YIDI
MY59")XQ[8.&_\>KVBBN[#YCB\-_"J->73[GH2X1>Z/E#7/V<_&6F9;3#::M'
MV\F3RW_[Y? _(FO/=8\)>(- D9-9T:]L]O5I8&"GZ-T/X&OO&D95=<, P/4$
M5[]#BK%0TJQ4OP?^7X&3H1Z'Y[T5]P:Q\,_!FN[SJ/AVQ9Y/O2Q1^4Y/KN7!
MKA-7_9I\*7:.=*O=0TZ0_=!<2H/P(R?^^J]RCQ1@YZ5$X_BOP_R,G1ET/EJB
MO;M4_9B\06ZEM)UJPO<?PS(T)/\ Z$/UKC-3^"WC[2D9Y= EN$7^*UD27/T"
MG/Z5[%'-L#6^"JOF[?G8APDNAPE%7KW1-5TS/]HZ9>6F.OGV[QX_,51KT8R4
ME>+N0%%%%, HHHH *ZWX7:&/$7Q-T2P==T7V@2RC_83YS_+'XUR5>[?LPZ'Y
M^O:OK<B96V@6WC8CHSG)Q^"_K7G9IB/JV"J5.MM/5Z(N"O)(^DZ***_'3O"B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* *^H7D>G:9<WLYVQV\32N3V"C/]*^"M7U&75]9O-1N3F6[G>9R?5B3_ %KZ
MW^.NO#1/A3J"*VV;4"MI'S_>.6_\=!KX\K]!X4P_+1G7?5V^[_ASEKO5(***
M*^R.<*^D_P!F+0?(T+5M=D7FZF6WC/\ LH,G]6'Y5\V5]M_"W0AX=^&>C6)3
M;(;<32C_ &W^8_SQ7R_$^(]G@O9K>3_!:_Y&U%7E<ZZBBBOS0[ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@!&17&'4,/0C-85]X%\*:FS-?\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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84 %%%% !1110 4444 %%%% !1110!__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>8
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm139690545862192">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cover Page<br></strong></div></th>
<th class="th"><div>Dec. 13, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInformationLineItems', window );"><strong>Entity Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec. 13,  2023<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">PFIZER INC<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">1-3619<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">13-5315170<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">66 Hudson Boulevard East<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">New York,<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">NY<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">10001-2192<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">212<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">733-2323<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0000078003<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember', window );">Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInformationLineItems', window );"><strong>Entity Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, $.05 par value<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">PFE<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSE<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=pfe_NotesDue20271.000Member', window );">Notes Due 2027, 1.000% [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInformationLineItems', window );"><strong>Entity Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">1.000% Notes due 2027<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">PFE27<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSE<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=pfe_NotesDue20271.000Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=pfe_NotesDue20271.000Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>9
<FILENAME>pfe-20231213_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2023"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:pfe="http://www.pfizer.com/20231213"
  xmlns:us-gaap="http://fasb.org/us-gaap/2023"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="pfe-20231213.xsd" xlink:type="simple"/>
    <context id="c-1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
        </entity>
        <period>
            <startDate>2023-12-13</startDate>
            <endDate>2023-12-13</endDate>
        </period>
    </context>
    <context id="c-2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-12-13</startDate>
            <endDate>2023-12-13</endDate>
        </period>
    </context>
    <context id="c-3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">pfe:NotesDue20271.000Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-12-13</startDate>
            <endDate>2023-12-13</endDate>
        </period>
    </context>
    <dei:EntityCentralIndexKey contextRef="c-1" id="f-27">0000078003</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag contextRef="c-1" id="f-28">false</dei:AmendmentFlag>
    <dei:DocumentType contextRef="c-1" id="f-1">8-K</dei:DocumentType>
    <dei:DocumentType contextRef="c-1" id="f-2">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="c-1" id="f-3">2023-12-13</dei:DocumentPeriodEndDate>
    <dei:DocumentPeriodEndDate contextRef="c-1" id="f-4">2023-12-13</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName contextRef="c-1" id="f-5">PFIZER INC</dei:EntityRegistrantName>
    <dei:EntityRegistrantName contextRef="c-1" id="f-6">PFIZER INC</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="c-1" id="f-7">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber contextRef="c-1" id="f-8">1-3619</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber contextRef="c-1" id="f-9">13-5315170</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="c-1" id="f-10">66 Hudson Boulevard East</dei:EntityAddressAddressLine1>
    <dei:EntityAddressPostalZipCode contextRef="c-1" id="f-11">10001-2192</dei:EntityAddressPostalZipCode>
    <dei:EntityAddressCityOrTown contextRef="c-1" id="f-12">New York,</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="c-1" id="f-13">NY</dei:EntityAddressStateOrProvince>
    <dei:CityAreaCode contextRef="c-1" id="f-14">212</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="c-1" id="f-15">733-2323</dei:LocalPhoneNumber>
    <dei:WrittenCommunications contextRef="c-1" id="f-16">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial contextRef="c-1" id="f-17">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer contextRef="c-1" id="f-18">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer contextRef="c-1" id="f-19">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle contextRef="c-2" id="f-20">Common Stock, $.05 par value</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="c-2" id="f-21">PFE</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="c-2" id="f-22">NYSE</dei:SecurityExchangeName>
    <dei:Security12bTitle contextRef="c-3" id="f-23">1.000% Notes due 2027</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="c-3" id="f-24">PFE27</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="c-3" id="f-25">NYSE</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany contextRef="c-1" id="f-26">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>10
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M@F& 92>@N)?GB;R"5=%Q'ER 412D[ 84-_$/TH>!F:UD@IE'C4C7\YK,0WL
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MVJ5QD L9>3T\$MP>:4#M.*2VBZD8_1!2:5K5N %(MB6/:<Z10J[4+!XUA])
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MX_T,:3?D@6)8YL_X>\87_QO.\1'"[K\_L;S63AI_YHOA/UY_ 5!+ 0(4 Q0
M   ( )D]C5<'04UB@0   +$    0              "  0    !D;V-0<F]P
M<R]A<' N>&UL4$L! A0#%     @ F3V-5S\0+D;N    *P(  !$
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M;',O+G)E;'-02P$"% ,4    " "9/8U7&445]3<!   G @  #P
M    @ ')$   >&PO=V]R:V)O;VLN>&UL4$L! A0#%     @ F3V-5R0>FZ*M
M    ^ $  !H              ( !+1(  'AL+U]R96QS+W=O<FMB;V]K+GAM
M;"YR96QS4$L! A0#%     @ F3V-5V60>9(9 0  SP,  !,
M ( !$A,  %M#;VYT96YT7U1Y<&5S72YX;6Q02P4&      D "0 ^ @  7!0
#

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.23.3</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>3</ContextCount>
  <ElementCount>22</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>2</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="pfe-20231213.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0000001 - Document - Cover Page</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pfizer.com/role/CoverPage</Role>
      <ShortName>Cover Page</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" isOnlyDei="true" isUsgaap="true" original="pfe-20231213.htm">pfe-20231213.htm</File>
    <File>pfe-20231213.xsd</File>
    <File>pfe-20231213_def.xml</File>
    <File>pfe-20231213_lab.xml</File>
    <File>pfe-20231213_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="28">http://xbrl.sec.gov/dei/2023</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>15
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "pfe-20231213.htm": {
   "nsprefix": "pfe",
   "nsuri": "http://www.pfizer.com/20231213",
   "dts": {
    "inline": {
     "local": [
      "pfe-20231213.htm"
     ]
    },
    "schema": {
     "local": [
      "pfe-20231213.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd",
      "https://xbrl.sec.gov/country/2023/country-2023.xsd",
      "https://xbrl.sec.gov/dei/2023/dei-2023.xsd"
     ]
    },
    "definitionLink": {
     "local": [
      "pfe-20231213_def.xml"
     ]
    },
    "labelLink": {
     "local": [
      "pfe-20231213_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "pfe-20231213_pre.xml"
     ]
    }
   },
   "keyStandard": 22,
   "keyCustom": 0,
   "axisStandard": 1,
   "axisCustom": 0,
   "memberStandard": 1,
   "memberCustom": 1,
   "hidden": {
    "total": 2,
    "http://xbrl.sec.gov/dei/2023": 2
   },
   "contextCount": 3,
   "entityCount": 1,
   "segmentCount": 2,
   "elementCount": 29,
   "unitCount": 0,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2023": 28
   },
   "report": {
    "R1": {
     "role": "http://www.pfizer.com/role/CoverPage",
     "longName": "0000001 - Document - Cover Page",
     "shortName": "Cover Page",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "dei:DocumentType",
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pfe-20231213.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "dei:DocumentType",
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pfe-20231213.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://www.pfizer.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Registrant Name",
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://www.pfizer.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Tax Identification Number",
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "pfe_NotesDue20271.000Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.pfizer.com/20231213",
     "localname": "NotesDue20271.000Member",
     "presentation": [
      "http://www.pfizer.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Notes Due 2027, 1.000% [Member]",
        "label": "Notes Due 2027, 1.000% [Member]",
        "documentation": "Notes Due 2027, 1.000% [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://www.pfizer.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Written Communications",
        "label": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "Security12bTitle",
     "presentation": [
      "http://www.pfizer.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Title of 12(b) Security",
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_EntityInformationLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityInformationLineItems",
     "presentation": [
      "http://www.pfizer.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Information [Line Items]",
        "label": "Entity Information [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://www.pfizer.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Soliciting Material",
        "label": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://www.pfizer.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Incorporation, State or Country Code",
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CityAreaCode",
     "presentation": [
      "http://www.pfizer.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "City Area Code",
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfStockDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ClassOfStockDomain",
     "presentation": [
      "http://www.pfizer.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Class of Stock [Domain]",
        "label": "Class of Stock [Domain]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://www.pfizer.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, City or Town",
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://www.pfizer.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pre-commencement Tender Offer",
        "label": "Pre-commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://www.pfizer.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Central Index Key",
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://www.pfizer.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Local Phone Number",
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "TradingSymbol",
     "presentation": [
      "http://www.pfizer.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trading Symbol",
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cover [Abstract]",
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://www.pfizer.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, State or Province",
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://www.pfizer.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pre-commencement Issuer Tender Offer",
        "label": "Pre-commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://www.pfizer.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Security Exchange Name",
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://www.pfizer.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity File Number",
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://www.pfizer.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amendment Flag",
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://www.pfizer.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Emerging Growth Company",
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "us-gaap_StatementClassOfStockAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementClassOfStockAxis",
     "presentation": [
      "http://www.pfizer.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Class of Stock [Axis]",
        "label": "Class of Stock [Axis]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://www.pfizer.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Postal Zip Code",
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentType",
     "presentation": [
      "http://www.pfizer.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Type",
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://www.pfizer.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Period End Date",
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://www.pfizer.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Address Line One",
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommonStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockMember",
     "presentation": [
      "http://www.pfizer.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common Stock [Member]",
        "label": "Common Stock [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntitiesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntitiesTable",
     "presentation": [
      "http://www.pfizer.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entities [Table]",
        "label": "Entities [Table]",
        "documentation": "Container to assemble all relevant information about each entity associated with the document instance"
       }
      }
     },
     "auth_ref": []
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r2": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r3": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r4": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r5": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Section": "14a",
   "Number": "240",
   "Subsection": "12"
  },
  "r6": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>16
<FILENAME>0000078003-23-000120-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0000078003-23-000120-xbrl.zip
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M^ J03/K4?FFSX&5.V$2@@%8C[F4!>@6OJL4@3N:FX"MW9JG4*6<9RAA&R3.
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M:.&Q".@Q7DE<C$U%.F\']9"UH,E1PA/Q$OPZXD?0QG-FM[0\98[G443Z67*
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MZ@B0P)<&AE@+1J5G> X[*]A100#20:21##$UX8VQ7P%7)2FJ\(SU.1<G[!Z
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MEB=':R2B4U5Z8XX_X,)VB4]0[6^<@A:G%IR:!TOZH'I,W>OX!P^I/=^&U#;
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M=\!+="*60QW>3H-@2P+=77(2],=PWXYNY[[]-$S".?QGDD^C7_X?4$L#!!0
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MV>;M]5'9S0YV*0N.6E@TF>,A-8Q+S$<Z=C.!)8:J0"0+SL@ W&JVSJ99L6[
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M#YZ"&(G^NIHQ<_QCCW#<0A\95_5#8OUS1D$0,A4JXGJ.!E26!$/27J,S@M+
MF#-/'0CY?Z9_[X&8OQ#^GPGQCX!>+1;=&4,4]*&O>S(%*?4F2.)D_\@?4UAZ
M)$ $5X("!2G4V/E^3<3/*^K&(O,0]*"PCOCDQ'F$[&/50O/F C#NFNU12I>2
MA#4I5X C.5A)I-&<6*\T<=8&HT2 ].',OO9HTQ/=[RS#L4+VZ*_UY>Q!2+
M_?+JQ?)R]Z=["O35B_\"4$L#!!0    ( )D]C5=HHG&B[ P  (1V   4
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MT@J5%-$T8 19_R4:8G%&4!H8<^9GB>XIK#ST8CN03#R]]:1:[P(M]7)95T,
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M1?J8U<V V)?FYVA=)^/BQ?R!H!C>YU?/;D_T/_K_97[U[']02P$"% ,4
M" "9/8U7.M)97WHC  #NYP  $0              @ $     97AH.3EP<C$R
M,3,R,RYH=&U02P$"% ,4    " "9/8U7IC[?KGD0  #VA   $
M    @ &I(P  <&9E+3(P,C,Q,C$S+FAT;5!+ 0(4 Q0    ( )D]C5>+%P!5
M)P,  +$*   0              "  5 T  !P9F4M,C R,S$R,3,N>'-D4$L!
M A0#%     @ F3V-5]:>6IMA"    #P  !0              ( !I3<  '!F
M92TR,#(S,3(Q,U]D968N>&UL4$L! A0#%     @ F3V-5VBB<:+L#   A'8
M !0              ( !.$   '!F92TR,#(S,3(Q,U]L86(N>&UL4$L! A0#
M%     @ F3V-5R=\R2L)"   FSX  !0              ( !5DT  '!F92TR
E,#(S,3(Q,U]P<F4N>&UL4$L%!@     &  8 @0$  )%5      $!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
